Florida International University

FIU Digital Commons
FIU Electronic Theses and Dissertations

University Graduate School

11-8-2019

The Role of inositol Polyphosphate-4-Phosphatase Type II b
(INPP4B) in Obese Models and Endocrine Cancers
Manqi Zhang
mzhan016@fiu.edu

Follow this and additional works at: https://digitalcommons.fiu.edu/etd
Part of the Biochemistry Commons, Cancer Biology Commons, Cell Biology Commons, and the
Nutritional and Metabolic Diseases Commons

Recommended Citation
Zhang, Manqi, "The Role of inositol Polyphosphate-4-Phosphatase Type II b (INPP4B) in Obese Models
and Endocrine Cancers" (2019). FIU Electronic Theses and Dissertations. 4333.
https://digitalcommons.fiu.edu/etd/4333

This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It
has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU
Digital Commons. For more information, please contact dcc@fiu.edu.

FLORIDA INTERNATIONAL UNIVERSITY
Miami, Florida

THE ROLE OF INOSITOL POLYPHOSPHATE-4-PHOSPHATASE TYPE II B
(INPP4B) IN OBESE MODELS AND ENDOCRINE CANCERS

A dissertation submitted in partial fulfillment of
the requirements for the degree of
DOCTOR OF PHILOSOPHY
in
BIOCHEMISTRY
by
Manqi Zhang

2019

To: Dean Michael R. Heithaus
College of Arts, Sciences and Education
This dissertation, written by Manqi Zhang, and entitled The Role of Inositol
Polyphosphate-4-Phosphatase Type II B (INPP4B) in Obese Models and Endocrine
Cancers, having been approved in respect to style and intellectual content, is referred to
you for judgment.
We have read this dissertation and recommend that it be approved.
_______________________________________
Jeffrey Boyd
_______________________________________
Yuan Liu
_______________________________________
Yukching Tse Dinh
_______________________________________
Irina Agoulnik, Major Professor

Date of Defense: November 8, 2019
The dissertation of Manqi Zhang is approved.

_______________________________________
Dean Michael R. Heithaus
College of Arts, Sciences and Education

_______________________________________
Andrés G. Gil
Vice President for Research and Economic Development
and Dean of the University Graduate School

Florida International University, 2019

ii

© Copyright 2019 by Manqi Zhang
All rights reserved.

iii

DEDICATION
I dedicate this dissertation to my parents YajuanXu and Xiaonan Zhang who support me
all the time and encourage me to pursue my dreams.

iv

ACKNOWLEDGMENTS
I would like to express my gratitude to the many people who have helped and supported
me in completion of this work, stood by me and made my time special in the graduate
school. More specifically, I would like to extend my sincere thanks to the people below.
First and foremost, I would like to express my deepest appreciation to my major
professor, Dr. Irina Agoulnik, without whom this thesis would not have been possible. I
was intrigued by Dr. Agoulnik’s ideas that made this work attractive and valuable. Dr.
Agoulnik has provided me with numerous opportunities to gain knowledge and skills and
encouraged me to overcome the obstacles. With her excellent mentorship, I have gained
invaluable experience in writing, scientific research, social communication, and
presentation. Therefore, I am extremely grateful to Dr. Agoulnik for her great support and
care throughout my Ph.D. years. She helped me become a better student in school and a
better person in life.
I would like to extend my sincere thanks to my committee members, Dr. Yuan Liu, Dr.
Yuk-Ching Tse-Dinh, and Dr. Jefferey Boyd for their support and constructive advice. I
would like to especially thank Dr. Tse-Dinh for her help and guidance during my
Dissertation Year Fellowship (DYF) application. I would like to give special thanks to Dr.
Liu, the biochemistry graduate program director, for keeping track of my progress during
the years.
I would like to acknowledge the National Cancer Institute which funded my stipend and
research between 2015 to 2018. I also would like to acknowledge the Department of
Chemistry and Biochemistry and University Graduate School at FIU for the financial
support.

v

I had the pleasure of working with great peers and laboratory members. Many thanks to
Egla Suarez who has offered me patient instructions and unwavering supports when I first
joined the lab and to Judy Vasquez who provided unselfish assistance and guidance for my
lab work and my writing. I thank Yasemin Ceyhan and Carlos Sandoval for interesting
research discussion and their research fellowship. Special thanks to Dr. Alexander
Agoulnik’s lab, especially to Courtney Myhr, Maria Lopez, Dr. Elena Kaftanovskaya, and
Dr. Alexander Agoulnik for their endless help and support in the course of our experiments.
Especially I am very grateful to Dr. Elena who has introduced me to the world of histology.
I would like to extend my gratitude to our collaborators for their generous help and
invaluable contribution to our research. Dr. Jean Vacher has provided the mouse model;
Dr. Lubov Nathanson has helped us analyze the gene expression profiles and taught us a
number of bioinformatics’ approaches to data analysis; Dr. Michael Ittmmann has
contributed to the histopathological analysis of mouse prostate sections; Dr. Nancy Weigel
has provided unique cell lines and insightful suggestions for our work, especially the
studies related to the prostate cancer.
I would like to acknowledge the Biochemistry Program and a great team of stuff that
worked in the Chemistry and Biochemistry Program, especially Magali Autie, Jackelyn
Marcos, and Dr. Watson Lees for their time and help to make our life much easier.
I am also grateful to Dr. Xiaotang Wang who has given me the opportunities to join the
FIU Biochemistry and introduced me to Dr. Irina Agoulnik’s lab, the beginning of this
great adventure. I very much appreciate my friend Wei Zhang and Wenjie Wang, who
have been there for me during these five years with their support and encouragement.

vi

Last but not least, I’m deeply indebted to my parents Yajuan Xu and Xiaonan Zhang for
their unwavering support. I would like to thank them for encouraging me to pursue my
dreams. Their belief in me keeps me moving towards accomplishing my dreams.

vii

ABSTRACT OF THE DISSERTATION
THE ROLE OF INOSITOL POLYPHOSPHATE-4-PHOSPHATASE TYPE II B
(INPP4B) IN OBESE MODELS AND ENDOCRINE CANCERS
by
Manqi Zhang
Florida International University, 2019
Miami, Florida
Professor Irina Agoulnik, Major Professor
INPP4B is a dual-specificity phosphatase and a tumor suppressor in prostate and breast
cancers. Progression of the prostate and breast cancers depends on the androgen receptor
(AR) or estrogen receptor alpha (ERα) signaling, respectively. In this work we
demonstrated that INPP4B reprograms ERα transcriptional activity in breast cancer.
INPP4B maintains expression and protein levels of progesterone receptor (PR), an ERα
direct target gene required for mammary gland development. Consistently we
demonstrated that Inpp4b knockout severely impairs lateral branching in the mammary
gland of maturing virgin females. In advanced prostate cancer, activation and
transcriptional reprogramming of AR frequently coincides with the loss INPP4B. We
showed that INPP4B regulates AR transcriptional activity in part through inhibiting the
oncogenic signaling pathways Akt and PKC. The high-fat diet (HFD) and obesity have
been linked to the development of metabolic dysfunction and the promotion of multiple
cancers. In obese individuals, the insulin and fatty acid mediated signaling activates AKT
and PKC pathways which are involved in metabolic disorders. Therefore, we investigated
the roles of INPP4B in obese models. Males were susceptible to diet-induced obesity,
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exhibited significant inflammation of the adipose tissue, hepatosteatosis, and type 2
diabetes. Obese HFD Inpp4b-/- males developed high grade prostatic intraepithelial
neoplasia. Similar to humans, female knockout mice were protected from the insulin
resistance despite extreme obesity and fibrotic hepatosteatosis. Development of steatosis
in Inpp4b-/- mice was caused by increased constitutive proteolytic activation of lipogenic
transcription factor SREBP1 in liver. Activated SREBP1 along with the HFD caused
increased expression of PPARγ and other genes that are involved in de novo lipogenesis
leading to the development of non-alcoholic fatty liver disease (NAFLD). Metabolic and
steroid signaling changes caused mammary gland hyperplasia in obese knockout females.
In conclusion, INPP4B is a tumor suppressor that regulates steroid receptor signaling and
protects mice from high-fat diet induced metabolic disorders and neoplastic changes.
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CHAPTER 1: INTRODUCTION
1.1.

Phosphoinositide and phosphatidylinositol signaling
Phosphatidylinositol (PI) is an important lipid component of the cell membrane that

activates essential metabolic processes and signal transduction. PI is an acidic phospholipid
that consists of a glycerol backbone connected with two fatty acid chains inserted into the
cytosolic layer of the cell membrane and esterified with phosphate connected to a watersoluble inositol head group (Figure 1-1). Phosphorylation of the inositol hydroxyl groups
at D-3, D-4, or D-5 position creates various phosphoinositides with distinct signaling
functions: PI3P, PI4P, PI5P, PI(3,4)P2, PI(4,5)P3, PI(3,5)P2, PI(3,4,5)P3 (Figure 1-2).

Figure 1-1. The structure of phosphatidylinositol.

Phosphoinositides are a family of phospholipids found in both the plasma and cytoplasmic
membranes (1). They play an essential role in signal transduction, intracellular membrane
trafficking, cytoskeleton remodeling, cell growth, and survival (2, 3). The maintenance of
phosphoinositide homeostasis is critical for the cellular function. The conversion between
different types of phosphoinositides is mainly dependent on phosphoinositide phosphatases
and kinases (4, 5). Currently, there are 35 phosphatases have been identified in mammals
(1). The inositol polyphosphate 3-phosphatases include myotubularin (MTM), MTM
related proteins (MTMR), and phosphatase and tensin homolog deleted on chromosome 10
(PTEN). The inositol-4-phosphatases include four enzymes: INPP4A, INPP4B,
TMEM55A, and TMEM55B, which preferentially dephosphorylate 4-phosphate. There are
ten known 5-phosphatases, which include INPP5B, INPP5E, OCRL1, PIPP, SAC2,
SHIP1/2, SKIP, and SYNJ1/2 (1). Some other phosphatases can remove 2 or more
phosphate groups simultaneously. Changes or mutations of phosphoinositide phosphatases
have been implicated in diabetes, cancer, cardiovascular, and neuronal diseases (2, 3, 6).
Among phosphatidyl polyphosphate phosphatases, INPP4B and PTEN display the most
significant structural and functional similarity.

2

Figure 1-2. Major phosphoinositide interconversion diagram shows the structure of
phosphatidylinositol and its various phosphorylated forms.

3

1.2.

Inositol polyphosphate 3-phosphatase: PTEN

PTEN is the most well-described phosphoinositide phosphatase. PTEN functions as a
phosphoinositol phosphatase that can hydrolyze the phosphate at D-3 position of the
inositol ring of PI(3,4,5)P3, PI(3,4)P2, PI3P, and Ins(1,3,4,5)P4 (7, 8). Loss of
heterozygosity of PTEN is observed in human cancers (2, 9). Somatic homozygous
mutations of PTEN have been found in human glioblastoma, prostate, kidney, lung,
endometrial, bladder, and breast cancer (10-13). The germline mutations of PTEN are
associated with Cowden’s disease (14). In the mouse model, the homozygous PTEN
knockout causes embryonic lethality (15) while the heterozygous PTEN knockout results
in the development of neoplasias in colon, prostate, uterus, and thyroid (15-17). Previous
studies demonstrated that PTEN functions as a tumor suppressor by negatively regulating
oncogenic PI3K/AKT pathways. The tumor suppressor function of PTEN mainly depends
on lipid phosphatase activity. However, Jiang et al. have shown that PTEN directly
dephosphorylated Insulin receptor substrate (IRS1), a mediator of insulin/IGF1 signaling,
through protein tyrosine phosphatase activity (18).
The crystal structure analysis revealed that PTEN has an N-terminal dual-specificity
phosphatase domain that consists of five standard central β sheets surrounded by six α
helices. Carboxyterminal region contains a C2 domain formed by two antiparallel β sheets
connected by two short α helices and a PDZ-binding domain (8, 19, 20) (Figure 1-3). The
N-terminal domain includes a consensus dual-specificity phosphatase catalytic motif CX5R
that forms an active-site pocket to accommodate not only PI(3,4,5)P3 but also
phosphoproteins (19). The C2 domain binds phospholipids while the PDZ-BD is involved
in protein-protein interactions (8, 21).

4

Figure 1-3. Introduction of PTEN functional domains. The human PTEN has four functional
domains: N-terminal 3’phosphoase domain (blue) with catalytic motif (C124X5R) of dualspecificity phosphatase, a C2 binding domain (orange), a carboxyl-terminal tail domain (C-tail)
(yellow), and a PDZ-binding domain (PDZ-BD) (grey).

Figure 1-4. Introduction of INPP4B DNA locus, transcript, and protein domains.
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1.3.

Inositol polyphosphate 4-phosphatase: INPP4B

1.3.1. Gene locus, splice variants and patterns of protein expression of INPP4B
First INPP4 transcript was isolated from rat brain in 1995 (22) and subdivided into two
classes, INPP4A and INPP4B. The INPP4B function was firstly reported by Norris et al.
in 1997 (23). The human INPP4B gene is around 824 Kb and is located on chromosome
4q31.21, as seen in Figure I-4. Human INPP4B is comprised of 27 exons of which 23 are
protein-coding (Ensembl). The coding region starts from exon 5 and ends in exon 27 (24)
(Figure I-4). Croft et al. recently isolated a novel variant of INPP4B, called INPP4B-S; this
variant incorporates extra 27 bp from the sequence between exon 15 and 16 whereas the
exons 20-24 are spliced. The mouse Inpp4b gene is located on chromosome 8, and the
mouse INPP4B protein has two isoforms INPP4Bα and INPP4Bβ that are produced by
alternative splicing. The INPP4Bα distributed in the cytoplasm while INPP4Bβ localized
to the Golgi apparatus (25). Both isoforms are similar to the human and rat homologs. The
INPP4B is widely expressed in multiple human and murine tissues such as
breast/mammary gland, ovary, adipose tissue, bladder, testis, prostate, etc. (Figure 1-5 AB)
1.3.2. Biochemistry and structure of INPP4B
The human INPP4B is similar in structure to PTEN. It has a conserved C2 lipid-binding
domain at the N terminus, an NHR2 domain, and a C-terminal dual phosphatase domain,
as seen from Figure I4 (25, 26). The dual phosphatase domain allows INPP4B to function
as a dual-specificity phosphatase, capable of dephosphorylation of both lipid and protein
substrates (27). Multiple studies have shown that INPP4B preferentially binds with
PI(3,4)P2, PI(4,5)P2, and Ins(1,3,4)P3 (23, 28, 29). However, low but biologically
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significant levels of PI(3,4,5)P3 hydrolysis by INPP4B were observed in murine thyroids
(31). Our lab has shown that INPP4B reduces the phosphorylation of tyrosines on the AKT
(32). Guo et al. have shown that INPP4B dephosphorylates PTEN, which causes
downregulation of PTEN in colon cancer (33).
Unlike PTEN, INPP4B mutations are not frequently observed in human cancers. Our lab
previously generated the mutation of cysteine in the catalytic site CX5R of INPP4B gene.
The C842A mutation abolishes both lipid and phosphatase activity (28, 32) ( ). The K846M
mutation completely abolishes lipid phosphatase activity but does not affect the
phosphoprotein phosphatase activity (PTP) (32). The INPP4B D847E mutant ablates the
PTP activity and significantly reduces the phosphatase activity of lipid substrates,
PI(3,4)P2 and PI(4,5)P2 (32).
Table 1. Introduction of INPP4B mutation and corresponded activity

Mutation of

Lipid phosphatase activity

Protein phosphatase

INPP4B

PI(3,4)P2

PI(4,5)P2

I(1,3,4)p3

activity

C842A/S

Abolished

Abolished

Abolished

Abolished

K846M

Abolished

Abolished

Abolished

Remained

D847E

Abolished

Abolished

Reduced

Abolished

K843M

Abolished

Unchanged

Reduced

Increased
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Figure 1-5. INPP4B expression in human and mouse tissues. (A) Comparative INPP4B expression
in 27 human tissues were determined by RNA-sequencing. The RNA levels were presented in
Consensus Normalized eXpression (NX) and data were acquired from The Human Protein Atlas
(proteinatlas.org). (B) INPP4B expression in different mouse tissues from 123 mouse cell types
and primary tissues (RPJNA66167) (30). Data were presented in Reads Per Kilobase of transcript
(RPKM).
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1.3.3. PI signaling network (Figure 1-6)
Class I PI3Ks synthesize the lipid messenger PI(3,4,5)P3. PTEN, dephosphorylates
PI(3,4,5)P3, another lipid messenger that can activate the AKT pathway. PTEN is known
as a tumor suppressor in prostate cancer not only because of the inhibition of AKT
signaling, but also because the loss of PTEN in prostate cancer promotes the expression of
androgen receptor (AR) and amplifies AR transcriptional activity. The activation of AR is
essential for prostate development and initiation and progression of prostate cancer (34,
35). When PTEN is deficient in thyroid tumors, INPP4B suppresses tumor proliferation by
dephosphorylating PI(3,4,5)P3 (31).
The two lipid substrates of INPP4B, PI(3,4)P2 and PI(4,5)P2, are important second
messengers for AKT and PKC signaling (Figure I6). AKT is known as a serine/threonine
protein kinase and an effector of PI3K signaling (it is activated in a PI3K-dependent
manner) (36, 37). The PI3K products, PI(3,4,5)P3 and PI(3,4)P2, recruit AKT to the
membrane by binding to the C-terminal pleckstrin homology (PH) domain (38), which
results in the conformation change in AKT leading to the phosphorylation by
PDK1/mTORC2 at Thr308 and Ser473 (39). The AKT pathway has more than 200 known
protein downstream targets that are involved in protein synthesis, survival, migration,
proliferation, and glucose metabolism (40, 41). The AKT signaling is oncogenic in
numerous tissues such as lung, ovary, breast, and prostate (42-45). INPP4B
dephosphorylates PI(3,4)P2 and inhibits oncogenic AKT pathway in breast, ovarian,
thyroid, and prostate cancers (29, 31, 46, 47). Therefore, INPP4B is considered as a tumor
suppressor in these epithelial cancers.
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PI(4,5)P2 is another lipid substrate of INPP4B and is hydrolyzed by phospholipase C
(PLC) into inositol triphosphate and diacylglycerol (DAG). DAG activates both
conventional (α,β,γ) and novel (ε,δ,η,θ) kinases of the PKC family (48-50). The atypical
PKC isoforms (ζ and ι/λ) are activated by lipid membrane components other than DAG
(51). Protein levels of PKC α, ε, ζ are increased in prostate and other cancers (52). We have
previously shown that INPP4B suppresses PKC signaling in prostate cancer cells and
normal mouse prostate (53, 54).
In turn, Akt directly binds and phosphorylates AR on serines 213 and 791 (55-58).
Phosphorylation of these sites affects AR activity in a cell-specific manner (56, 57).
INPP4B regulates both Akt and PKC activity and is capable of dephosphorylating
phosphoproteins opening a possibility for either direct or indirect regulation of AR
phosphorylation and activity. To date, numerous publications suggest that INPP4B is
playing essential roles in the prostate, breast, ovarian, and other cancers.
1.4.

Prostate cancer and INPP4B role in prostate cancer

1.4.1. Prostate cancer requires androgen receptor (AR) for initiation and
progression
Prostate cancer is the second most common male malignancy and the second leading cause
of cancer death for men in America (59). In 2018, 164,690 men were diagnosed with
prostate cancer, and around 18% of them have died (60). Localized prostate cancer is
managed with radical prostatectomy. Once the cancer spreads beyond the prostate capsule,
androgen-ablation therapy (ADT) is the first-line treatment (61). Effective at first, this
treatment always leads to biochemical recurrence of castration-resistant prostate cancer
(CRPC). The pathogenesis of prostate cancer progression mainly depends on the activation
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of the AR signaling (62). Treatment with androgen receptor inhibitors such as enzalutamide
(MDV3100) or abiraterone, prolongs patient survival but inevitably results in the
emergence of adaptive AR signaling and resistance to castration therapies (63). Death from
prostate cancer is due mainly to the development of metastatic castration-resistant prostate
cancer (CRPC) (64). The high risk of advanced prostate cancer and the development of
resistance after treatment underscore the importance to identify more effective targets for
prostate cancer, especially for CRPC (60, 64, 65).
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Figure 1-6. INPP4B signaling network. In response to the extracellular signals, PI3K, PI4K, and
PI5K generate diacylglycerol derivatives (PI3P, PI(3,4)P2, PI(4,5)P2, PI(3,4,5)P3) that are
important for the activation of downstream pathways including AKT and PKC pathways. The AKT
and PKC pathways can phosphorylate the AR and change AR transcriptional activity. PTEN, 3’phosphatase, terminates downstream signaling by dephosphorylating PI(3,4,5)P3. PTEN
suppresses AR activity and AR stability through the AKT pathway. INPP4B, 4’-phosphatase
dephosphorylates PI(3,4)P2 that activates AKT pathway, and PI(4,5)P2 that activates PKC
pathway. Additionally, INPP4B enhances SGK3 activation by producing PI3P. SHIP, 5’phosphatase converts PI(3,4,5)P3 to PI(3,4)P2.
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1.4.2. AR structure and AR splice variants
The AR signaling is required for the development, function, and homeostasis of the
prostate, as well as the initiation and proliferation of the prostate cancer. AR is a liganddependent transcription factor that regulates gene expression. The AR protein has an
amino-terminal domain (NTD), a DNA binding domain (DBD), a hinge region, and a
ligand-binding domain (LBD) (Figure 1-7) (66, 67). The classical action of AR signaling
starts with the binding of androgen to LBD of AR, causing translocation of AR into the
nucleus where AR dimerizes and binds to the androgens response element (ARE) in the
promoter region of the target genes and recruits the other transcriptional coregulators to
facilitate transcription(68).
Various mechanisms contribute to the development of CRPC. The AR signaling can be
activated by altered expression of AR coregulators, overexpression of AR, gain-of-function
mutations, and alternative splicing of AR mRNA (69-71). Expression of AR splice variants
that lack ligand-binding domain in advanced prostate cancer stimulates AR activity during
castration therapies (Figure 1-7). The lack of LBD allows these active isoforms to regulate
gene expression independently of ligand. Another mechanism of antiandrogen resistance
is upregulation of the glucocorticoid receptor (GR) (72). The ChIP-sequencing data
revealed that AR and GR share highly overlapping cistrome profiles suggesting the GR
activation can restore expression of a subset of AR target genes that are involved in cellular
proliferation and resistance to therapies (72, 73). Additionally, the resistance can also be
induced by overexpression of AR coregulators (74) or ligand-independent AR activation
via cytokines or growth factors such as, IL6 or IGF1 (75). Thus, AR is a pivotal factor in
prostate cancer initiation and its progression to CRPC (68).
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1.4.3. The tumor-suppressive function of INPP4B in prostate cancer
A global analysis of copy number alteration, transcriptome, and mutation data from 181
primary prostate tumors and 37 metastatic tumors has revealed that INPP4B is lost in 8%
of the primary tumors and 47% of the metastasis (76). Using prostate tissue microarrays,
our laboratory has shown INPP4B protein level is reduced in human prostate cancer
compared to healthy prostate specimens (47). Our laboratory is the first to demonstrate
INPP4B tumor-suppressive function in prostate. We have shown that the loss of INPP4B
is associated with accelerated biochemical recurrence in high proliferating prostate tumors
(47). In prostate cancer cells, AR binds to INPP4B locus and induces INPP4B expression.
INPP4B suppresses oncogenic AKT pathway, inhibit cell proliferation, migration, and
invasion in vivo (47, 53, 77).
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Figure 1-7. Organization of the AR gene and domains of the full length and splice variants’ of AR
protein.

Figure 1-8. Structures of ERs.
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1.5.

Breast cancer and INPP4B role in breast cancer

1.5.1. Four major subtypes of breast cancer
Breast cancer has the second highest incidence and mortality rates in women after
cutaneous cancers (CDC). Currently, four major molecular subtypes of breast cancer have
been identified that exhibit distinct levels of expression of estrogen receptor α (ERα) and
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These
subtypes include luminal A, luminal B, HER2-positive, and triple-negative breast cancer
(Table 2) (78). The luminal A breast cancer has a relatively low proliferation rate, while
the triple-negative breast cancer has the worst patient survival.

Table 2. Molecular subtypes of breast cancer

Subtypes

Characteristics

Proliferation INPP4B
rate
level

Therapies

ERα

PR

HER2

Luminal A

+++

+++

-

Low (+)

+++

Hormone therapy

Luminal B

+

+

+/-

++

+~+++

HER2
enriched

-

-

+

+++

Triplenegative

-

-

-

++++

Chemotherapy and
hormone therapy
Chemotherapy and
treatment targeted to
HER2
Chemotherapy

+

-

1.5.2. ERα and PR
ER are hormone receptors of the nuclear receptor family and has a similar structure as AR
(Figure 1-8). The estrogen and ER complex bind to the estrogen-responsive element (ERE),
recruit cofactor and regulate the expression of a subset of genes. The estrogen is important
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to stimulate the development of normal breast and promote progression of breast cancer.
Alternatively, the growth factors like EGF or IGF can phosphorylate ER to mediate ERmediated transcriptional regulation (79). ERα and ERβ, encoded by ESR1 and ESR2
respectively, are two distinct estrogen receptors (ER). ERα and ERβ have distinct
expression patterns and some structural differences in NTD and LBD (Figure I8). Indeed,
ERα but not ERβ is required for the development of the mammary gland structure (80).
More importantly, estrogen promotes proliferation in the presence of ERα but suppresses
proliferation with ERβ that makes ERβ a potential therapeutic target (81).
Among breast cancer patients, more than 70% of breast cancers express ERα (82). Both
luminal A and B breast cancers expresses ERα and PR but at different levels. ERα functions
as an estrogen-activated transcription factor and regulates a variety of genes that govern
cell proliferation and survival in cancerous and non-cancerous breast epithelial cells (83).
Even though patients whose tumors are ERα-positive mostly benefit from ER antagonists
and inhibitors of estrogen synthesis, both early or late relapses still occur. Some of the main
mechanisms of resistance are the activation of signaling pathways such as PI3K/Akt and
p44/42 MAPK which phosphorylate and activate ER independently of ligand binding (8486).
Currently, both ERα and PR are used as biomarkers and targets in breast cancers. PR is an
ERα regulated gene and has two isoforms PRA and PRB that are encoded by the same gene
PGR. Progesterone mediated activation of PR is known to inhibit ERα activity and
estrogen-induced tumor growth (87, 88). Depletion of PR does not affect the establishment
of mammary gland structure but affects mammary ductal branching (89).
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1.5.3. HER2 enriched breast cancer
Human epidermal growth factor receptor 2 (HER2) is a transmembrane receptor tyrosine
kinase that regulates cell differentiation, proliferation, and survival. Even though HER2
does not have its own ligand, it is activated by dimering with other HER family members
in breast cancer enriched with HER2 (90). Estrogen mediated activation of ER signaling
can also activates HER signaling (91). HER2 is amplified in 15–20% of breast cancers
(92). Specific treatments for HER2-enriched breast cancer include tyrosine kinase
inhibitors (lapatinib) and recombinant humanized monoclonal antibodies that inhibit HER2
dimerization or binding to HER3 (pertuzumab or trastuzumab) (93).
The activation of HER2 signaling in breast cancer promotes tumor cell proliferation
through various pathways including oncogenic PI3K/AKT/mTOR signaling and MAPK
signaling (94). PTEN loss is considered as a potential predictor to evaluate whether patients
could benefit from anti-HER2 treatments (95). INPP4B level is reduced in HER2-enriched
breast cancers (96) suggesting a tumor-suppressive function of INPP4B in HER2-enriched
cancer.
1.5.4. Triple-negative breast cancer (TNBC)
Approximately 10-20% of breast cancers are classified as TNBC characterized by high
proliferative rate and relatively poor survival compared to the other types of breast cancers.
TNBC is characterized by increased inflammatory infiltrates and a mesenchymal
phenotype which are a characteristic of advanced breast carcinomas (97). TNBC is defined
by the absence of ER, PR, and HER2, all of which are used as therapeutic targets.
Therefore, chemotherapy is the primary established treatment for TNBC patients.
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Currently, there are studies to explore novel approaches targeting damage and repair
pathways, androgen-mediated signaling, PI3K pathway, among others (97, 98).
1.5.5. Paradoxical role of INPP4B in breast cancer
In human mammary epithelial cells, knockdown of INPP4B activates AKT pathway and
facilitates cell motility, proliferation, anchorage-independent growth, and threedimensional growth (29, 46). Overexpression of INPP4B in a xenograft mouse model
suppresses tumor growth (29). INPP4B protein is highly expressed in luminal tumors (82).
In ERα+ breast cancer, there is a tight correlation between INPP4B and ERα (46). In basallike cancers, loss of INPP4B expression is 61% specific and 99% sensitive with the highest
odds ratio at 108 among all other biomarkers (99). Loss of heterozygosity (LOH) of
INPP4B is common in triple-negative breast cancer (46). This suggested that INPP4B is a
marker for triple-negative breast cancer (46, 99). However, in a subset of breast cancer,
INPP4B can play a tumor-promoting role. Gasser et al. have demonstrated that
glucocorticoid-regulated kinase 3 (SGK3), a protein amplified in PIK3CA mutant breast
cancers, is essential for the proliferation and migration of breast cancer cells (100, 101).
SGK3 is a PI3K effector and overexpression of SGK3 activates AKT signaling. A product
of INPP4B lipid phosphatase enzymatic activity, PI3P, activates SGK3. The knockdown
of INPP4B abolishes SGK3 mediates cell growth (101).
1.6.

Crosstalk between INPP4B regulated signaling and metabolic disorders

Currently, the known roles of INPP4B in normal physiology are restricted to regulation of
osteoclastogenesis and protection from osteoporosis (28). No reports are published on the
role of INPP4B in metabolic pathways. However, its direct downstream targets, Akt and
PKC, are intricately involved in obesity-related metabolic disorders.
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1.6.1. Metabolic disorders
The prevalence of obesity in the United States has been increasing for almost 50 years
(102). Currently, more than two-thirds of adults are overweight or obese. The high caloric
diet induced obesity is recognized as a leading cause of metabolic disorders and chronic
inflammation which increase the risk of health complications including insulin resistance,
cardiovascular disease, type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD),
and even cancers (103, 104). All of these are affecting a large number of people and lead
to increased morbidity and mortality rates (105, 106).
In 2015, around 35% of the US population were pre-diabetic or were diagnosed with
diabetes. Taking into account the underreporting of these conditions, the prevalence of
prediabetes and diabetes is likely more than 50% (107). The nutritional excess is a major
cause of T2D that is universally represented by an insufficient insulin sensitivity and
impaired blood glucose clearance. The hormone insulin is secreted by the beta cells of the
pancreas, binds with insulin receptor (INSR) on the plasma membrane, and promotes the
uptake of glucose into liver, muscle, and adipose tissues (108). The disruption of insulin
signaling causes hyperglycemia, followed by hyperinsulinemia and subsequent T2D in
mice and humans (109).
In normal condition, insulin suppresses adipocyte lipolysis, a metabolic process that breaks
down triglycerides into fatty acid and glycerol (110). Rats fed with high fat diet develop
insulin resistance associated with reduced insulin-mediated inhibitory action on lipolysis
(111). This phenomenon causes the release of excessive fatty acid and glycerol from
adipose tissue, promotes the hepatic glucose production, and eventually leads to the
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elevated blood glucose (112, 113). Therefore, it is important to study the insulin signal
transduction and the factors that induced insulin resistance.
1.6.2. AKT signaling under normal diet or high fat feeding conditions
To maintain the glucose homeostasis, insulin signaling suppresses gluconeogenesis in the
liver through the AKT pathway. Under normal condition, insulin-mediated AKT pathway
suppresses Foxo1 and down regulates key enzymes that are involved in gluconeogenesis
(114, 115). With the feeding of high-fat diet (HFD), the insulin mediated inhibition of
Foxo1 is abolished. The upregulated Foxo1 increases the level of gluconeogenesis leading
to high blood glucose (112). On the other hand, AKT pathway is activated by insulin
signaling and promotes de novo lipogenesis (DNL), a process of fatty acid synthesis. In
diabetic models, the stimulation of DNL results in the development of NAFLD,
characterized by the accumulation of ectopic lipid content in hepatocyte. The inhibition of
AKT or AKT downstream target mTOR blocks the insulin-induced upregulation and
activation of SREBP1 (116, 117). Overexpression of SREBP1, a primary transcriptional
regulator of DNL, causes liver steatosis (118). From healthy state to T2D state, insulin
resistance selectively lost regulation on gluconeogenesis whereas insulin signaling
continues to active lipogenesis leading to hyperglycemia and hypertriglyceridemia (119)
(120).
1.6.3. Activation of PKC pathways under obese conditions
The ectopic lipid accumulation in the insulin-resistant state can lead to abnormal activation
of intracellular signaling pathways. PI(4,5)P2 is cleaved by PLC into diacylglycerol (DAG)
and phosphoinositol. DAG is a lipid metabolite that binds and activates conventional PKCs
and novel PKCs as mentioned in the previous section. Early reports link the accumulation
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of DAG with insulin resistance. In turn, the activated PKC signaling further impairs insulin
resistance (106). Studies have shown that in obese rodents with T2D, the level of PKCα,
β, δ, ε, and ζ are significantly increased compared to lean rodents (121, 122). Dr. Shulman
and his group demonstrated that the activation of PKCε is involved in the developing of
hepatic insulin resistance (123). The whole-body or liver-specific inactivation of PKCδ
enhances the insulin signaling and suppresses the gluconeogenetic and lipogenic function
(124). Consistently, overexpression PKCs causes hepatic steatosis, insulin resistance, and
glucose intolerance (124, 125). One potential mechanism contributing to the PKCs induced
impairment of insulin signaling is that the PKC phosphorylates IRS-1 at S1101, which has
been shown to block IRS-1 tyrosine auto-phosphorylation and activation of the AKT
pathway (126).
1.7.

INPP4B knockout (Inpp4b-/-) mouse model

Mouse INPP4B protein shares 96% identity with human INPP4B and has the same
functional domains (25). C2 lipid-binding domain of INPP4B is 91% identical between
human and mouse (127). We used INPP4B knockout mouse model to investigate the role
of INPP4B in normal physiology of lean and obese mice. The Inpp4b-/- mouse model was
generated and kindly provided by Dr. Jean Vacher. The Inpp4b-/- mouse model was created
by inserting LoxP sites into introns surrounding exon 11 of Inpp4b (Figure 1-9). Deletion
of exon 11 during Cre-Lox germ line recombination led to frame shift in the mRNA and
generation of STOP codon at 217 codon (28). Using this mouse model, Dr. Vacher’s group
described INPP4B as a negative regulator of the osteoclastogenesis and bone mass (28).

22

Figure 1-9. The diagram shows the generation of Inpp4b-/- mouse model.

1.8.

OVERVIEW

Tumor suppressors are proteins that help control cell growth. The studies of tumor
suppressor reveal potential mechanisms to inhibit tumor cell growth, which might
contribute to the development of novel treatments. INPP4B and its enzymatic activity as a
dual-specificity phosphatase were first described in 1997 (128). However, the
physiological functions of INPP4B remained unknown until 2005, when an RNAi-based
genetic screening revealed that INPP4B might be a suppressor of neoplastic transformation
of the mammary epithelial cells (129). Multiple subsequent studies identified the tumorsuppressive function of INPP4B in different types of malignancies. Barnache et al. revealed
that INPP4B was lost in malignant proerythroblasts with reduced AKT activation (130).
Gewinner et al. first demonstrated that INPP4B is a tumor suppressor in breast and ovarian
cancers (29). Our lab has described the tumor-suppressive function of INPP4B in prostate
cancer (47). With the accumulation of evidence, INPP4B is now emerging as a tumor
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suppressor in multiple epithelial cancers including prostate, breast, ovarian, thyroid, and
bladder cancers (29, 31, 46, 47, 131) (Figure 1-10).
In our previous publications, we showed two of the INPP4B lipid substrates, PI(3,4)P2 and
PI(4,5)P2, activate AKT and PKC signaling, respectively. INPP4B-mediated inhibition of
tumor growth depends mainly on the suppression of oncogenic AKT pathway. In obese
mice and humans, PKC signaling is activated in livers, skeletal muscles, and adipose
tissues. Activation of PKC is tightly associated with the ectopic lipid accumulation and
insulin resistance in liver and muscle of obese model (123). While there is ample evidence
of INPP4B tumor suppressive function, its physiological roles in metabolism and
homeostasis of healthy tissues are not known. Therefore, I set out to delineate the
mechanisms of tumor suppressive functions of INPP4B in breast and prostate cancer
models and INPP4B role in diet regulated metabolic processes.
In Chapter One, we investigated the relationship between INPP4B and AR signaling in
prostate cancer cells and normal mouse prostate. Taylor et al. have previously shown the
activation of AR signaling and loss of INPP4B or PTEN both happened in metastatic
prostate cancer (132). Using prostate cancer cell lines, we showed that INPP4B regulates
AR transcriptional activity partially through oncogenic signaling pathways Akt and PKC.
Using an Inpp4b-/- mouse model, we observed that INPP4B suppressed on Akt and PKC
signaling pathways and modulated AR transcriptional activity in the healthy mouse
prostate. Our data demonstrated that INPP4B modulates AR activity in healthy prostate
and its loss contributes to the oncogenic reprogramming of the AR-dependent
transcriptome in prostate cancer.
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In Chapter Two, we investigated INPP4B function in a mouse model of diet-induced
obesity in males (DOI). We observed an accelerated weight gain in INPP4B deficient obese
mice. We showed that in lean male mice, loss of INPP4B caused hyperglycemia and insulin
resistance. Combined with HFD, Inpp4b loss led to type 2 diabetes represented by an
increased level of blood insulin and glucose. More importantly(133), Inpp4b deficient male
mice had an enhanced activation of SREBP1 in the liver which, along with the high-fat
diet, caused increased expression and activity of PPARG and other lipogenic pathways,
leading to liver steatosis. Additionally, we observed the development of high-grade
prostatic intraepithelial neoplasia in HFD Inpp4b-/- mouse but not the HFD WT mouse
prostates suggesting the synergetic function of INPP4B and HFD in prostates.

Figure 1-10. Role of INPP4B in human cancers. Each box shows when INPP4B is lost, the
phenotype displayed by each type of cancer.
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In Chapter Three, we explored the function of INPP4B in breast cancer cells and obese
female mice. ERα and PR are steroid receptor that regulate mammary gland development
homeostasis, neoplastic transformation and breast tumor progression. Using gene
expression microarrays, we demonstrated INPP4B modulated ERα and PR transcriptional
activities. Specifically, INPP4B loss reduced PR protein level and altered expression of PR
target genes. Phenotypically, we observed reduced ductal branching of mammary gland in
Inpp4b-/- female mice. Using the HFD treated wild-type female mice as controls, we
showed Inpp4b deletion led to extensive weight gain and white adipose tissue (WAT)
expansion in HFD female mice. Most importantly, we observed increased lipid content and
development of fibrosis in livers of HFD Inpp4b-/- females suggesting that INPP4B protect
obese female mice from developing NAFLD.
Overall, we demonstrated INPP4B regulates hormone receptor signaling in prostate and
breast normal epithelium and cancer cells, stimulates mammary gland development in
female mice, and protects obese male mice from developing prostatic epithelial neoplasia.
As a metabolic regulator, INPP4B protect the mice from diet induced weight gain and
metabolic diseases such as NAFLD, hyperglycemia, and T2D.
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CHAPTER 2: THE ROLE OF INOSITOL POLYPHOSPHATE 4-PHOSPHATASE
TYPE II IN PROSTATE CANCER CELLS AND NORMAL MOUSE PROSTATE
2.1.

ABSTRACT

Activation and transcriptional reprograming of AR in advanced prostate cancer frequently
overlaps with the loss of two tumor suppressors, INPP4B and PTEN, which are highly
expressed in human and mouse prostate epithelium. While regulation of AR signaling by
PTEN has been described by multiple groups, it is not known whether the loss of INPP4B
affects AR activity. Using prostate cancer cell lines, we showed that INPP4B regulates AR
transcriptional activity and oncogenic signaling pathways AKT and PKC. Analysis of gene
expression in prostate cancer patient cohorts showed a positive correlation between
INPP4B expression and both AR mRNA levels and AR transcriptional output. Using an
Inpp4b-/- mouse model, we demonstrated that INPP4B suppresses AKT and PKC signaling
pathways and modulates AR transcriptional activity in normal mouse prostate. It has been
previously shown that the high fat diet activates AKT pathway in mouse prostate. We
showed that the loss of INPP4B further increases AKT phosphorylation in dorsolateral and
ventral lobes of mice fed with the high fat diet. Remarkably, levels of PTEN protein levels
and phosphorylation of S380 were the same in Inpp4b-/- and WT males, suggesting that
observed changes were due exclusively to the loss of INPP4B. Our data show that INPP4B
modulates AR activity in normal prostate and its loss contributes to the AR-dependent
transcriptional profile in prostate cancer.

2.2.

INTRODUCTION
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INPP4B has been identified as a tumor suppressor in ovarian, breast, thyroid, bladder, and
prostate cancers (29, 46, 131, 134, 135). INPP4B functions as a dual specificity
phosphatase, capable of dephosphorylation of both lipid and protein substrates similar to
PTEN (127). Remarkably, both PTEN and INPP4B are lost in nearly half of all metastatic
prostate cancers (132).
Preferred substrates for INPP4B lipid phosphatase activity are PI(3,4)P2, PI(4,5)P2, and
Ins(1,3,4)P3 (31, 136). However, low but biologically significant levels of PI(3,4,5)P3
hydrolysis by INPP4B were observed in murine thyroids (31). Both PI(3,4,5)P3 and
PI(3,4)P2 bind and activate the oncogenic AKT signaling pathway which facilitates cell
survival, migration, and invasion in multiple malignancies including prostate cancer (41,
137). The INPP4B substrate PI(4,5)P2 is required for activation of both conventional
(α,β,γ) and novel (ε,δ,η,θ) kinases of the PKC family (138, 139). PI(4,5)P2 is hydrolyzed
by phospholipase C (PLC) into inositol triphosphate and diacylglycerol (DAG) which
binds and activates PKC (48). A separate class of PKC, the atypical PKC isoforms (ζ and
ι/λ) are activated by lipid components other than DAG [9]. Protein levels of PKC α, ε, ζ
are increased in prostate and other cancers (140). We and others found that INPP4B
suppresses PKC signaling in prostate, breast, and gastric cancer cells (136, 141, 142). The
activation of the androgen receptor (AR) is essential for prostate development and for the
initiation and progression of prostate cancer (34, 35). With prostate cancer progression the
AR transcriptional profile changes from one of differentiation to proliferation (134). This
change is due, in part, to the activation of cell signaling pathways and posttranslational
modifications of AR. We and others have shown that the loss of INPP4B activates AKT
signaling (29, 31, 134). In turn, AKT directly binds and phosphorylates serine 213 and 791
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on AR (56-58). Phosphorylation of these sites affects AR activity in a cell specific manner
(56, 57). In mice, a prostate specific Pten-/- knockout leads to AKT activation and nearly
complete loss of the AR protein, which is partially reversed by treatment with AKT
inhibitors (143). PKC was reported to phosphorylate AR on S213 and S578 increasing AR
transcriptional activity and regulating its turnover (144). In mouse models, overexpression
of PKCε led to prostate hyperplasia and intraepithelial neoplasia, in part, by stabilizing AR
levels (145, 146).
In this report we investigated whether INPP4B modulates transcriptional activity and
turnover of the full-length AR, and the AR splice variant, AR-V7. Unlike full length AR,
AR-V7 was unable to induce INPP4B gene expression. Loss of INPP4B significantly
altered a subset of AR, as well as AR-V7 target genes, without altering AR protein levels.
We showed that INPP4B suppresses AKT and PKC signaling in independently derived
prostate cancer cell lines. To test whether these signaling pathways were responsible for
the change in AR activity, we used AKT and PKC specific inhibitors to mimic INPP4B
expression. We determined that some, but not all changes in AR target gene expression are
mediated by the activation of AKT and PKC. Similar to our observations in human prostate
cancer cell lines, induction of prostate specific AR target genes was reduced in Inpp4b-/mice. In the prostate, Inpp4b knockout mice expressed similar levels of AR, PTEN, and pPTEN when compared to their wild-type (WT) littermates. Interestingly, the Inpp4b
knockout mice displayed increased activity of AKT, PKCζ and PKCβII in the prostate, as
indicated by increased phosphorylation levels. Our data indicate that INPP4B suppresses
AKT and PKC signaling pathways and modulates AR transcriptional output in human and
mouse models.
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Figure 2-1. Loss of INPP4B changes AR transcriptional activity. (A) Three dimensional rendering
of INPP4B distribution. Cells were fixed and stained with INPP4B primary and Alexa Fluor
conjugated secondary antibodies (white). The nuclei were counterstained with DAPI (blue). (B)
Early-stage LNCaP cells were transfected with either a control (Ctrl) or two independent INPP4B
specific siRNAs (INPP4B-1, INPP4B-2) for 48 hours in medium supplemented with FBS. Protein
levels of AR, INPP4B, and tubulin were compared by western blotting. (C). LNCaP cells were
transfected as in (B). RNA was extracted and used in microarray analysis. Gene expression was
compared to that of AR regulated genes in LNCaP cells. (D) GSEA analysis of INPP4B regulated
genes using an AR transcriptional signature in LNCaP cells (GSE60721). (Normalized Enrichment
Score = 1.84, p <0.001). E-J. LNCaP cells were cells were tandem transfected with either control
or INPP4B siRNAs with 48 hour intervals. Forty eight hours later cells were placed in medium
supplemented with 10% CSS and treated with either vehicle (ethanol) or 0.1 nM R1881 for 24
hours as indicated. RNA was analyzed for expression of INPP4B (E), KIAA1324 (F), SYTL2 (G),
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TARP (H), TMPRSS2 (I), and NNMT (J). Expression was normalized to 18S. ** p < 0.01, *** p <
0.001.

2.3.

RESULTS

2.3.1. Loss of INPP4B changes AR transcriptional output.
INPP4B depletion accelerates LNCaP cell proliferation, an androgen dependent feature of
this prostate cancer cell line. To determine whether INPP4B modulates AR transcriptional
activity we performed gene expression microarray analysis. Endogenous INPP4B is
generally localized to the cell membrane and cytoplasm (Figure 2-1 A), while AR shuttles
between the cytoplasm and nucleus (147). Two INPP4B specific siRNAs were used to
knock down INPP4B in LNCaP cells (Figure 2-1 B). Forty-eight hours later INPP4B
protein levels were nearly undetectable while AR protein levels were unchanged (Figure
2-1 B). We chose this time point to evaluate changes in transcript levels using Affymetrix
microarrays (Figure 2-1 A). DHT-dependent AR output in LNCaP cells was previously
reported by our laboratory (148). To determine whether INPP4B regulates AR target genes,
we analyzed changes in the expression of the AR target genes in LNCaP cells transfected
with either control or INPP4B specific siRNAs. A subset of AR target genes were
significantly affected by the knockdown of INPP4B (Figure 2-1 C). To confirm INPP4B
regulation of AR transcriptional activity we used gene set enrichment analysis (GSEA). An
AR signature was created using our previously reported microarray analysis of AR target
genes, GSE60721 (148). The analysis indicated that the AR signature is significantly
represented among INPP4B regulated genes (Normalized Enrichment Score = 1.84, p <
0.001) (Figure 2-1 D). We next investigated whether INPP4B expression correlates with
AR mRNA levels and AR signature in prostate cancer patients. As seen from Figure 2-2
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Figure 2-2. Correlations between INPP4B expression and AR expression and transcriptional
output. (A) LNCaP cells were transfected with either control or INPP4B siRNAs and incubated in
complete serum for 48 hours. RNA was extracted and analyzed using Illumina microarrays. Gene
expression was clustered in biological replicates. (B) TCGA and Taylor cohorts were used to
examine correlations between INPP4B, AR, and PTEN mRNAs and Nelson and Hieronymus AR
signatures.
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B, in both Taylor and TCGA cohorts there are statistically significant positive correlations
between INPP4B and both AR mRNA and two AR signatures, Nelson and Hieronymus.To
determine whether INPP4B regulates basal or androgen dependent gene expression, we
knocked down INPP4B, treated cells with vehicle or 0.1 nM R1881, and compared the
expression of three AR induced genes and three AR reduced genes in LNCaP cells. The
three AR induced genes most strongly regulated by INPP4B were: T Cell Receptor Gamma
Alternate Reading Frame Protein (TARP), Transmembrane Protease Serine 2 (TMPRSS2)
and Nicotinamide N-Methyltransferase (NNMT) (Figure 2-3 A). Three AR suppressed
genes most strongly regulated by INPP4B are; Estrogen-Induced Gene 121 Protein
(KIAA1324), Synaptotagmin-Like 2 (SYTL2), Phospholipase A2, Group IIA (PLA2G2A)
(Figure 2-3 B). Both induction and repression of these genes was reduced following
INPP4B knockdown in medium supplemented with FBS (Figure 2-3 C-D). As seen in
Figure 2-1 E, INPP4B siRNA significantly reduced INPP4B mRNA levels in cells cultured
with CSS serum treated with vehicle or R1881. Since INPP4B is a primary AR target gene
(134), its expression was increased with R1881 treatment. Following INPP4B knockdown,
AR dependent repression of KIAA1324 and SYTL2 was abolished (Figure 2-1 F-G). While
both basal and R1881-dependent induction of TARP and TMPRSS2 were reduced (Figure
2-1 H-I), fold induction of NNMT was increased by INPP4B loss (Figure 2-1 J).
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Figure 2-3. INPP4B is required for optimal induction and repression of a subset of the AR
target genes. (A) LNCaP cells were plated in 10% CSS medium with either vehicle or 1nM R1881.
Twenty-four hours post-treatment, mRNA was collected and expression of AR target genes, TARP,
TMPRSS2, NNMT, was analyzed by RT-qPCR. (B) RNA from A was used to analyze expression
of SYTL2, PLA2G2A, and KIAA1324. (C) LNCaP cells were plated in 10% CSS medium. Next
day cells were transfected with control or INPP4B siRNA and treated with either control or vehicle
for 48 hours. RNA was extracted and analyzed for expression of TARP, TMPRSS2, NNMT by RTqPCR (D) RNA from C was used to compare expression of SYTL2, PLA2G2A, and KIAA1324. All
gene expression levels were normalized for 18S. Differences in gene expression between treated
and control cells was statistically significant (p<0.01) in all panels of this figure.
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2.3.2. Reciprocal regulation of AR-V7 and INPP4B.
AR splice variants, including AR-V7, are expressed at the late stages of prostate cancer
and correlate with poor prognosis (149, 150). We have previously shown that INPP4B
expression is stimulated by androgens in LNCaP and VCaP cell lines and in primary
prostate cancer patient derived xenografts (134, 136). We used the LNCaPAR-V7/pHAGE cell
line which expresses an inducible AR-V7 variant (151) to test whether AR-V7 is able to
upregulate expression of endogenous INPP4B. Similar to the parental LNCaP cell line,
androgens increase expression of endogenous INPP4B (Figure 2-4 A) in LNCaPAR-V7/pHAGE
cell line, while AR-V7 splice variant fails to induce INPP4B expression (Figure 2-4 A lanes
5 and 6). Moreover, AR-V7 suppresses INPP4B expression on mRNA levels (Figure 2-4
B, bars 1 and 2). Expression of AR-V7 in LNCaPAR-V7/pHAGE, increased phosphorylation of
AKT and PKCβII in media supplemented with either CSS or FBS (Figure 2-4 A). To test
whether INPP4B modulates AR-V7 transcriptional activity we compared expression of
EDN2, an AR-V7 specific target gene in the LNCaPAR-V7/pHAGE cell line (151). As seen
from Figure 2-4 C, INPP4B knockdown significantly decreased the induction of EDN2.
These results suggest that INPP4B modulates AR-V7 transcriptional activity and that,
unlike full-length AR, AR-V7 is unable to induce INPP4B expression. Since AR-V7 has
many target genes in common with full length AR, we tested whether NNMT, TARP,
TMPRSS2, KIAA1324, and SYTL2 were regulated by both AR-V7 and INPP4B in
LNCaPAR-V7/pHAGE cell line. Similar to the parental LNCaP cell line, INPP4B knockdown
reduced basal transcription of NNMT without changing the ability of AR-V7 to induce its
expression (Figure 2-4 D). Both basal and AR-V7 - dependent regulation of TARP,
TMPRSS2, KIAA1324, and SYTL2 required INPP4B expression (Figure 2-4 E-H).
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Figure 2-4. Reciprocal regulation of AR-V7 and INPP4B. (A) LNCaP AR-V7/pHage cells were placed
in medium with 10% CSS or 10% TET FBS serum for 24 hours and treated with 50 ng/ml Dox or
1nM R1881 as indicated for an additional 36 hours. Protein level of INPP4B, AR-FL, AR-V7,
pPKC βII, and tubulin were assessed by Western blotting. (B, C) LNCaP AR-V7/pHage cells were
transfected with control or INPP4B siRNA and maintained in medium supplemented with 10%TET
serum. Forty-eight hours later cells were transfected again with control or INPP4B siRNAs and
treated with either vehicle or 25ng/ml Dox for additional 24 hours. Gene expression of INPP4B (B)
and EDN2 (C) were analyzed by RT-qPCR using 18S as a control. LNCaP AR-V7/pHage cells were
tandem transfected with either control or INPP4B siRNAs with 48 hour intervals. Forty-eight hours
later cells were placed in medium supplemented with 10% CSS with or without 30ng/ml Dox for
24 hours as indicated. RNA was analyzed for expression of NNMT (D), TARP (E), TMPRSS2 (F),
KIAA1324 (G), and SYTL2 (H). ** p < 0.01, *** p < 0.001.
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2.3.3. INPP4B regulates AR transcriptome via inhibition of PI3K/AKT and PKC
signaling pathways.
Based on the disparate spatial distribution of INPP4B and AR, we tested whether INPP4B
regulation of the AR transcriptome includes intermediate signaling pathways. We and
others have reported INPP4B regulation of the AKT pathway (29, 32, 33, 46, 134) and in
our previous reports we showed that overexpression of INPP4B in the PC3 cell line reduces
phosphorylation of PKCβII and PKCζ (136). As seen in Figure 2-5 A-C, INPP4B
knockdown increased phosphorylation of PKCζ on Thr410 (2.52 fold ± 0.77; 1.84 fold ±
0.19) and PKCβII on Ser660 (2.23 fold ± 0.09; 1.70 fold ± 0.04) in the androgen sensitive
cell lines LNCaP and VCaP, respectively, and upregulates phosphorylation levels of PKCζ
(1.89 fold ± 0.30) in the C4-2 cell line. As previously shown, INPP4B knockdown
increased pAKT levels in LNCaP cells (134). We confirmed that under our experimental
conditions, pAKT levels are increased 48 hours after INPP4B knockdown in LNCaP and
C4-2 cell lines (Figure 2-5 B-C). Since INPP4B suppresses both AKT and PKC pathways,
we tested whether their inhibitors could phenocopy the INPP4B regulation of AR induced
and repressed genes. Both induction and repression of these genes was reduced following
INPP4B knockdown (Figure 2-3 C-D). AZD5363 and bisindolymaleimide I (BIM-I) were
used to test whether INPP4B regulates AR transcriptional activity through the AKT and
PKC pathways, respectively. The inhibitor activity was confirmed by decreased
phosphorylation of the downstream target S6 protein (Figure 2-5 D). Similar to INPP4B
expression in control siRNA treated cells, PLA2G2A mRNA was reduced following BIMI and AZD5363 treatment and expression of KIAA1324 was decreased by PKC inhibitor
(Figure 2-5 E-F). AZD5363 increased expression of TARP and NNMT, as did expression
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Figure 2-5. Suppression of AKT and PKC signaling contributes to INPP4B regulation of AR
transcriptional activity. (A) VCaP cells were transfected with control, INPP4B, or PTEN specific
siRNAs individually. Proteins were extracted and assayed for levels of INPP4B, PTEN, pAKT,
pPKC βII, pPKC ζ, and β-tubulin by Western blotting. (B) C4-2 cells were transfected with control
or INPP4B siRNAs for 48 hours in medium supplemented with 10% FBS. Cellular lysates were
assayed for INPP4B, pAKT, pPKC βII, pPKC ζ, and tubulin by western blotting. (C) LNCaP cells
were transfected and assayed in parallel with B. (D) LNCaP cells were plated in complete medium
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and treated with indicated inhibitors for 8 hours. Protein extracts were assayed for AR, INPP4B,
pS6, and tubulin levels by Western blotting. (E-J) LNCaP cells were plated in medium
supplemented with 10% CSS with either vehicle or 1nM R1881. Twenty four hours later cells were
treated with vehicle (DMSO), 5uM AZD5363, or 2uM BIM-I for additional 8 hours. In parallel,
LNCaP cells were transfected with control or INPP4B siRNA for 48 hours in 10% CSS medium
supplemented with 1nM R1881. RNA was purified, reverse transcribed, and expression levels of
AR regulated genes PLA2G2A (E), KIAA1324 (F), TARP (G), NNMT (H), TMPRSS2 (I) and SYTL2
(J) compared by RT-qPCR. Expression levels were normalized to 18S. ** represents p < 0.01; ***
represents p < 0.001.

of INPP4B (Figure 2-5 G-H). However, lack of concordant regulation of TMPRSS2 and
SYTL2 (Figure 2-5 I-J) suggests additional modes of INPP4B regulation of AR activity.
2.3.4. INPP4B signaling in the normal mouse prostate.
To investigate the function of INPP4B in the normal prostate we used an Inpp4b-/- mouse
model with deletion of exon 11 (28) which results in a frame shift at codon 213 and the
generation of a stop signal at codon 217 (Figure 2-6 E). As expected, no expression of
INPP4B was detected in the prostates of Inpp4b-/- mice and immunohistochemical analysis
confirms the lack of INPP4B protein in prostate epithelial cells (Figure 2-7 A-B). Mutant
male mice were fully fertile and displayed no difference in body, prostate, and testis
weights (Figure 2-6 A-C). The ratio of seminal vesicles versus body weight showed modest
but statistically significant increase in Inpp4b-/- mice compared to age-matched WT males
(Figure 2-6 D).
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Figure 2-6. Body and urogenital organ weight comparison of 2 month old WT and Inpp4b-/- male
littermates. Two month old WT (N=9) and Inpp4b-/- (N=12) male littermates were euthanized and
their body, prostate, testis, seminal vesicle weight determined. (A) Body weight. (B) Prostate
weight normalized to body weight. (C) Testis weight normalized to body weight. (D) Seminal
vesicle weight normalized to body weight. (E) Inpp4b-/- mouse prostate cDNA was amplified,
sequenced, translated and aligned with WT mouse protein sequence NP_001019788. * signifies
stop codon. (F) Fold change and significance of Msmb, Pbsn, Nkx3.1, Apof, Clu, and Inpp4b
expression caused by prostate specific Pten deletion in gene sets GSE46473, GSE46799,
GSE24691 and GSE76822.
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Figure 2-7. Loss of INPP4B in mouse prostate activates PKC and AKT signaling without changing
AR levels. (A) Prostates from the 2 month old WT or Inpp4b-/- littermate males were dissected,
fixed in paraffin, sectioned, and stained with INPP4B antibodies and counterstained with
hematoxylin. (B-C) RNA was extracted from prostates of WT (N=11) or Inpp4b -/- (N=11)
littermates. Expression of Inpp4b (B) and AR (C) and was compared by RT-qPCR. Gene
expression was normalized for 18S. (D) Slides from A were stained with AR antibody and
counterstained with hematoxylin (E) Individual prostate lobes, anterior (AP), dorsolateral (DLP),
and ventral (VP), from four prostates of WT or Inpp4b-/- littermates were pooled, protein extracted,
and analyzed for AR, total PTEN, pPTEN, pPKC ζ, pPKC βII, pAKT, total AKT, and tubulin levels
by Western blotting. (F) Mice fed either normal chow or high-fat diet one month before euthanasia.
AP, DLP, and AP prostate lobes of WT or Inpp4b-/- were dissected and samples were pooled from
3 mice of the same genotype. Protein was extracted and analyzed for pAKT, total AKT, p44/42
MAPK, and tubulin levels by Western blotting.
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Consistent with our observations in prostate cancer cell lines, AR mRNA and protein levels
did not change in Inpp4b-/- mouse prostates compared to those of the WT mice (Figure 2-7
C-E). Anterior (AP), dorsolateral (DLP), and ventral (VP) prostate lobes of WT and
Inpp4b-/- mice had similar expression of AR protein (Figure 2-7 D-E). We observed an
increase of pPKCβII (3.98 fold ± 1.01) and pPKCζ (2.83 fold ± 0.39) in AP and increase
of pPKCβII (2.11 fold ± 0.24) and pPKCζ (2.28 fold ± 0.26) in DLP of the Inpp4b-/- mice
compared to the WT controls (Figure 2-7 E). Increase in pAKT levels in DLP (1.519 fold
± 0.084) and VP (1.508 fold ± 0.199) occurred without change in PTEN protein and
phosphorylation levels. It was previously shown that high fat diet causes increase in pAKT
levels in mouse prostate (152, 153). We investigated whether INPP4B inhibits oncogenic
AKT signaling in prostates of mice maintained on high fat diet. Consistent with previous
results, one-month exposure to 58% fat diet elevated pAKT levels in prostates of WT mice
(Figure 2-7 F). In Inpp4b-/- mice, the pAKT levels were further increased in DLP and VP
tissues (Figure 2-7 F).
2.3.5. INPP4B regulates AR transcriptional activity in normal mouse prostate.
To investigate whether INPP4B modulates AR target gene expression, we selected three
genes strongly induced by AR and three genes regulated by PTEN in the mouse prostate
(143, 154). In previous reports, DHT supplementation of castrated mice significantly
induced Microseminoprotein β (Msmb), Apolipoprotein F (Apof), and NK3 Homeobox 1
(Nkx3.1) (154). We show that INPP4B was required for their optimal expression (Figure
2-8 A-C). Expression of the AR and PTEN regulated genes probasin (Pbsn) and clusterin
(Clu) was similar in the prostates of WT and Inpp4b-/- age-matched males. Interestingly,
Pten knockout in the mouse prostate did not alter INPP4B mRNA levels in two
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independent microarray profiles (Figure 2-6 F). In human prostate cancer samples,
however, a weak but significant positive correlation was observed between INPP4B and
PTEN mRNA levels in TCGA and Taylor cohorts. This data suggests that INPP4B
regulates a subset of AR target genes and the PKC and AKT signaling pathways in the
mouse prostate. These changes are due specifically to the loss of INPP4B as the levels of
total and phosphorylated PTEN did not change. Thus, the phosphatases INPP4B and PTEN
participate in separate and nonredundant functions and exhibit a lack of reciprocal
regulation in the mouse prostate.

Figure 2-8. INPP4B is required for optimal expression of a subset of AR target genes in mouse
prostate. Whole prostates were dissected from 2 month old WT (N=11) and Inpp4b-/- (N=11)
littermates. RNA was extracted, reverse transcribed, and expression levels of Apof (A), Nkx 3.1
(B), Msmb (C), Pten (D), Pbsn (E) and Clu (F) were compared by RT-qPCR. Expression levels
were normalized for 18S expression.
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2.4.

Discussion:

Prostate cancer is dependent on AR signaling for its initiation and progression. During this
progression, AR signaling undergoes significant reprogramming to acquire predominantly
proliferative and pro-survival functions (155). The loss of PTEN and/or activation of
PI3K/AKT signaling in prostate cancer leads to the loss of AR protein and a corresponding
decrease in AR transcriptional output (143, 156). On the other hand, ERG and ETV1
expression in PTEN deficient prostate cancers reactivate AR transcriptional output (157).
Both PTEN and INPP4B are members of a dual specificity phosphatase family that
dephosphorylates lipids and phosphoproteins. Taylor et al reported similar copy number
alterations for both INPP4B and PTEN with prostate cancer progression (132). Our group
showed a decline in INPP4B protein levels in prostate cancer and a correlation of INPP4B
loss with biochemical recurrence (134). Thus we investigated how losing INPP4B affects
AR signaling.
We used the LNCaP cell line which expresses high levels of INPP4B and AR and is also
dependent on androgens for its proliferation (158). In LNCaP cells, INPP4B knockdown
modulated ability of AR to activate and repress target genes (Figure 2-1 F–J). Supporting
this observation, the AR transcriptional signature is significantly represented among genes
regulated by INPP4B in the LNCaP cell line (Figure 2-1 D). Importantly, statistically
significant correlations between INPP4B expression and AR mRNA levels and
transcriptional output were observed in the TCGA and Taylor cohorts. While it is well
established that PTEN regulates AR transcriptional output in prostate cancer, INPP4B
correlations with AR signatures were stronger than those of PTEN (Figure 2-2 B) in both
cohorts.
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Loss of INPP4B and gain of AR splice variant expression occurs most frequently in
advanced stages of prostate cancer (132, 159). We used a well characterized LNCaPARV7/pHAGE

cell line which retains endogenous full length AR and INPP4B expression and

signaling to investigate reciprocal regulation of INPP4B and AR-V7 (151, 160). Consistent
with its oncogenic function, AR-V7 is unable to induce expression of the tumor suppressor
INPP4B and may in fact reduce INPP4B expression (Figure 2-4 A-B). INPP4B however,
retains its ability to regulate AR-V7 transcriptional activity (Figure 2-4 C-H).
While AR shuttles between the nucleus and the cytoplasm in both a ligand dependent and
independent manner (147, 161), INPP4B has been shown to localize mostly to cytoplasmic
and membrane compartments (46, 136). This localization could be due in part to the
INPP4B C2 domain that binds phosphatidylinositol polyphosphates, a lipid component of
cellular membranes (162). Similar to observations in mammary epithelium and PC3 cells
(46, 136), INPP4B shows focal extranuclear localization in LNCaP cells (Figure 2-1 A).
Membranes contain the INPP4B lipid substrates PI(3,4)P2 and PI(4,5)P2 which activate
AKT and PKC respectively. Activation of PKC has been linked to AR phosphorylation
and prostate cancer progression (140, 163, 164) and was shown to regulate angiogenesis,
apoptosis, cell proliferation, invasion, and metastasis (163, 165-167). The PI3K/AKT
signaling pathway is activated in nearly half of primary prostate tumors and in all
metastatic prostate tumors (132). AKT regulation of AR signaling is well described both
in vitro and in vivo (57, 58, 143, 156). We and others have shown that both these pathways
are suppressed by INPP4B in multiple cell models (29, 33, 134) including LNCaP cells
(Figure 2-5 A-C). Since both AKT and PKC phosphorylate AR and regulate its activity
(56-58, 144) we tested whether these kinases mediate some of the INPP4B dependent
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changes in AR transcriptional activity. We reasoned that if treatment with inhibitor
mimicked the effect of INPP4B on gene expression, the corresponding kinase might
contribute to the INPP4B regulation of AR transcriptional activity. As seen from Figures
3E-3F, expression of KIAA1324 and PLA2G2A is lower in the presence of INPP4B. BIMI and AZD5363 decreased expression of KIAA1324 and PLA2G2A, respectively,
implicating PKC and AKT in the regulation of these genes. Both INPP4B and AZD5363
treatment increase expression of TARP and NNMT (Figure 2-5 H-J), suggesting that AKT
mediates INPP4B-dependent induction of these genes. However, INPP4B regulation of
SYTL2 and TMPRSS2 are due to mechanisms other than inhibition of PKC and PI3K/AKT
signaling. This could be attributed to INPP4B protein phosphatase (32, 33) or other
activities. We have shown that INPP4B can dephosphorylate AKT on pTyr residues, and
Guo et al have shown that INPP4B can bind to and dephosphorylate PTEN on
Ser380/Thr382/Thr383 residues (32, 33). Importantly, phosphorylation of AKT on Tyr176
and Tyr 284 positively correlates with prostate cancer progression and inversely correlates
with patient survival, (168) suggesting a role for INPP4B protein phosphatase activity in
prostate cancer progression.
To validate INPP4B regulation of AR activity in vivo we used an Inpp4b knockout mouse
(28). Deletion of exon 11 in this model causes a frame shift leading to the addition of four
amino acids after Ala 212 and protein truncation (Figure 2-6 E). Using antibodies to the
INPP4B amino terminus we did not detect any signal (Figure 2-7 A), suggesting that even
if the N-terminal portion of INPP4B is translated, it is not abundant in prostate epithelium.
Male Inpp4b-/- mice are fertile and their prostates are histologically normal (Figure 2-7 A
and D). Similar to our observations in prostate cancer cell lines, loss of INPP4B changed
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neither mRNA nor protein levels of AR (Figure 2-7 C-E). However, we detected significant
increase of pAKT in the dorsolateral and ventral prostate lobes and increased pPKCζ and
PKC βII in the anterior and ventral prostate lobes of Inpp4b-/- versus age-matched WT
males. Of note, the dorsolateral section of the mouse prostate is considered a functional
model for the human prostate peripheral zone, the site of origin for most prostate cancers.
Obesity is a risk factor for prostate cancer, especially in African American men (169). Here
we show that loss of INPP4B exacerbates activation of oncogenic AKT pathway in mouse
prostate caused by consumption of high fat diet.
Since levels of total and phospho-Pten S380 remained the same, PTEN is unlikely to have
contributed to these changes (Figure 2-7 E). To determine whether INPP4B knockout
modulates AR transcriptional activity in vivo we tested the levels of expression of AR
target genes in the mouse prostate (154). As shown in Figure 2-6 F, prostate specific Pten
knockout affected expression of a number of AR target genes (143, 156). Similar to PTEN,
Inpp4b knockout reduced expression of Apof, Nkx3.1, and Msmb mRNAs. Unlike prostate
specific Pten knockouts, we observed no induction of Clu or a decline in Pbsn mRNA
levels in Inpp4b-/- prostates. Thus, differential regulation of AR target genes and AR
protein levels signify nonredundant functions of INPP4B and PTEN in prostate epithelium.
In this report we show that INPP4B loss reprograms the AR transcriptional output and
activates PKC and AKT signaling in vitro and in vivo. INPP4B is lost at slightly higher
rate than PTEN with prostate cancer progression (132) and is a strong predictor of
recurrence (134). Our data shows that tumors that lack INPP4B have different mechanisms
of progression from those with PTEN loss and may require a different therapy.
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2.5.

Materials and Methods

Cell culture and reagents
The human prostatic carcinoma cell lines, LNCaP and VCaP, were purchased from ATCC
(Manassas, VA) and maintained under ATCC-recommended conditions. C4-2 cells were
obtained from UroCor (Oklahoma City, OK) and maintained in RPMI 1640 (Thermo
Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS). All
experiments were performed during first 6 passages after purchasing cell lines from ATCC.
FBS and charcoal stripped serum (CSS) were purchased from Sigma-Aldrich (St. Louis,
MO). LNCaPAR-V7/pHAGE was described previously (151) and was maintained in RPMI 1640
supplemented with tetracycline-screened FBS (TET FBS) (GE Healthcare, Chicago, IL)
and geneticin (Thermo Fisher Scientific). LNCaPAR-V7/pHAGE cells were treated with 25
ng/ml or 50 ng/ml Doxycycline (Dox) (Clontech Laboratories, Mountain View, CA) to
express inducible AR-V7. R1881 was purchased from Perkin Elmer (Waltham, MA). The
following cell signaling inhibitors were used: AZD5363 (Selleckchem, Houston, TX) and
BIM-I (AdipoGen, San Diego, CA).
Immunofluorescence
LNCaP cells were grown on etched coverslips and fixed and processed as previously
described (136). Fixed cells were incubated with INPP4B primary antibody (Cell
Signaling, Danvers, MA) at 1:1000 dilution in 4°C overnight and Alexa Fluor conjugated
anti-rabbit secondary antibody (Thermo Fisher Scientific) at 1:1000 dilution at 4°C for 1
hour. Cells were counterstained with DAPI (Sigma) and visualized using Axio Imager 2
(Zeiss, ST Petersburg, FL). Three dimensional rendering was performed using AxioVision
LE software (Zeiss).
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siRNA transfections
Noncoding control, INPP4B, and PTEN siRNAs were transfected at 50-100pmol siRNA
per well in 6 well cell culture plate using Lipofectamine RNAiMAX Reagent (Thermo
Fisher Scientific) as recommended by manufacturer. All siRNAs used in this manuscript
are listed in Table 3.
Table 3. siRNA sequences.
siRNA

stock number

non coding
control

4390843

non coding
control
PTEN
PTEN
INPP4B
INPP4B
INPP4B
FOXA1

4390844
custom made
custom made
custom made
s16826
104699

Sense

Antisense

CCAUUACAAGAUAUACAAU
AAACAUUAUUGCUAUGGGA
GAGCCUGAACUGCAUUAUU
CGAUGUCAGUGACACUUGA
GGAAACAGGGUCCUCUUUC
GCACUGCAAUACUCGCCUU

AUUGUAUAUCUUGUAAUGG
UCCCAUAGCAAUAAUGUUU
AAUAAUGCAGUUCAGGCUC
UCAAGUGUCACUGACAUCG
GAAAGAGGACCCUGUUUCC
AAGGCGAGUAUUGCAGUGC

Microarray Analysis
LNCaP cells were transfected with noncoding control or INPP4B specific siRNAs using
Lipofectamine RNAiMAX Reagent. After transfection, cells were maintained in complete
medium for 48 hours. RNA was extracted using Tri reagent (Molecular Research Center,
Cincinnati, OH). RNA was quantified, evaluated for quality, and analyzed using the
Illumina Human HT-12v4 expression Beadchip platform exactly as described in our
previous publication (136).
Gene Set Enrichment Analysis (GSEA)
GSEA

analysis

was

performed

using

JAVA

program

http://software.broadinstitute.org/gsea as previously described (148, 170). AR signature
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was generated from LNCaP which includes 422 genes significantly changed (p<0.01) after
48 hours of DHT treatment (GSE60721) (148).
Correlation with published AR signatures and key genes in prostate cancer cohorts
Previously published signatures of prostate cancer cells transcriptional response to
androgen were derived from the Gene Expression Omnibus (GEO), termed Hyeronimus
and Nelson AR signatures (171, 172) . We downloaded gene expression datasets from
multiple previously reported human prostate cancer specimen cohorts: Taylor et al. (132),
and The Cancer Genome Atlas (TCGA) (173). Within each dataset, we utilized the
expression of each gene to calculate its respective z-score for each sample, relative to the
normal prostate gland specimens available in that cohort. For each of two published
androgen-induced signatures, Nelson and Hieronymus, we computed the sum z-score for
each sample (the z-scores of downregulated genes were subtracted from the z-scores of
upregulated genes), as described previously (132). Finally, for each pair of genes or
signatures we computed the Pearson Correlation Coefficient R and associated p-value
using the R statistical system.
Western blotting
Proteins were extracted from cultured cells as previously described (136). Mouse prostate
tissue was homogenized in ice-cold RIPA buffer with protease and phosphatase inhibitors.
Cleared lysates were diluted to 4 µg/µl and 10-25 µg of protein was resolved on SDSPAGE. The proteins were transferred on nitrocellulose or PVDF membranes (GE
Healthcare). Blots were blocked in 5% BSA (Millipore Sigma, Billerica, MA), incubated
with primary antibodies against INPP4B, AR, pAKT S473, pPKC ζ T410, pPKC β S660,
PTEN, total AKT, pS6 S235/236, and β-tubulin at 4°C overnight (Table 4). Blots were
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washed and incubated with HRP conjugated secondary antibodies (Promega, Madison, WI)
for 1 hour. Signal was generated using SuperSignal West Pico Chemiluminescent HRP
Substrate (Thermo Fisher Scientific) and captured by Gel Logic 2000 imaging system with
Carestream Molecular Imaging software (Carestream, Rochester, NY).
Table 4. Antibodies used in CHAPTER 2.
Antibody
cat #
phospho-Akt S473
Cell signaling #4051
Total Akt
Cell signaling #4691
phospho-PKCζ T410
Cell signaling #2060
phospho-PKCβII S660
Cell signaling #9371
β-Tubulin
Millipore #05-661
PTEN
Cell signaling #9188
AR
Millipore #06-680
PKCε
R&D systems AF5134
AR-V7
Cell signaling #68492
Cell signaling #4857
pS6 S235/236

concentration
1:1000
1:1000
1:1000
1:1000
1:5000
1:1000
1:1000
1:1000
1:1000
1:1000

RRID
AB_331158
AB_915783
AB_561487
AB_2168219
AB_309885
AB_2253290
AB_310214
AB_2171918
AB_2799747
AB_2181035

Gene expression analysis
RNA was prepared from prostate cancer cells or mouse prostate using Tri Reagent
(Molecular Research Center). RNA concentration was determined using NanoVue Plus
(GE Healthcare BioSciences, Piscataway, NJ). RNA was reverse transcribed using Verso
cDNA synthesis Kit (Thermo Fisher Scientific). cDNA was used as a template for Real
Time PCR using master mix, primers, and probes from Universal ProbeLibrary (Table 5)
(Roche, Basel, Switzerland). Amplification and analysis was done using Roche 480
LightCycler (Roche).
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Table 5. Primers and corresponding probes used in CHAPTER 2.
Human gene primers and corresponding probe sets
Gene
Forward primers
reverse primers
KIAA1324
ggcaccgttaacttcgaatact
tggcactggtcattctgaac
PLA2G2A
ccgcactcagttatggcttc
agtgacacagcagcgatcc
NNMT
tgtgtgatcttgaagggaacag
cttgaccgcctgtctcaac
SYTL2
gcccgagctctttaaccaat
tccagattgccaaagtctcc
TARP
gacaattgttcaaaagatgcaaa
gatgatggcaaaatagaccaca
TMPRSS2
ctgatcacaccagccatgat
tatcccctatcagccaccag
INPP4B
tgtctgatgctgacgctaaga
ccacaaaccaatccagcaa
EDN2
gtcctcatctcatgcccaag
tagacgcactccttgtcgag
PSA
tccgtgacgtggattggt
cagggttgggaatgcttct
FOXA1
gtggctccaggatgttagga
gagtaggcctcctgcgtgt
FKBP5
ggatatacgccaacatgttcaa
ccattgctttattggcctct
RASSF3
gacgccgaggacttcttctt
tgctgaggtaactgtgggttt

Probe
67
53
63
17
15
44
41
17
75
-------

Mouse gene primers and corresponding probe sets
Forward primers
reverse primers
ccagtcccaattgtgtcaaa
tccctggtactgtccaaacg
acagcaccagaaagtctgagc
ctttctgacatctgctcacgga
tctcaatggccggactgtat
aggatgagtcggaggctatg
cgactgaacccgagtctgat
aatcacctgagtgtgagagaagg
cgtggtgttcatgtgacaaaa
ctcaaaggcctagtagcgttg
aggcacaagaggccctagat
ctgactgggaattgtgactcc
tcatcctcctgctcacactg
gctaagtaaattgtttgccaagg
caatcctgcccaggctaac
ctgctctgtcagcctctcg
tcatcctcctgctcacactg
gctaagtaaattgtttgccaagg
tctcaatggccggactgtat
aggatgagtcggaggctatg
cgtggtgttcatgtgacaaaa
ctcaaaggcctagtagcgttg

Probe
58
89
17
5
62
60
47
1
47
17
62

Gene
Ar
Inpp4b
Apof
Nkx3.1
Msmb
Pten
Probasin
α-Clusterin
Pbsn
Apof
Msmb
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ChIP assay
LNCaP cells were cultured in RPMI medium supplemented with 10% FBS until 90%
confluency. The medium was changed to 10% CSS RPMI. After 24 hours, cells were
treated with vehicle, 20 nM R1881, and 25 ng/ml Dox for 18 hours. At the end of the
treatment, 32% formaldehyde was added to the cells to crosslink proteins to DNA. After
30min, wash the cells with 1X PBS and harvest the cells. The cells pellets were
resuspended in SDS lysis buffer. The cell lysate was sonicated 30s for 10 times using
Bioruptor sonicator at 4 °C. The lysate was centrifuged and the supernatant was diluted
10 times using ChIP dilution buffer. The lysate was then incubated with AR, AR-V7, and
Igg antibodies overnight at 4 °C. The Protein G and A conjugated beads (Thermo Fisher)
were washed with TE buffer and the beads suspension was incubated lysates at 4 °C for 2
hours. The beads were washed with low salt wash buffer, high salt wash buffer, and TE
buffer. The beads were washed with elution buffer to acquire the extracts. The extracts
were reverse crosslinking by incubating with 1M NaHCO3 at 65˚C for 6 hrs. DNA was
extracted with QIAGEN PCR purification kit and DNA products were used for RT-qPCR
using primers in Table 6. All buffers mentioned in this section were listed in Appendix
with detailed recipes.
Table 6. Primers used in ChIP assay.
INPP4B
tcttcttcccacctgactattttc
chr4:143,516,774
PSA enhancer
INPP4B intron2
INPP4B
enhancer

tctaggtcccgatcgactgt
aggtgagctacaagcaaggaa
attggtggctcaaaatccaa
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gccatgttttcaggtcatca
tgagcgctgccttattctg
tctgaataactcatgatattgggaaa
gcaagagaaagaagatacaaaacca

Animal Studies
Animals were housed at AAALAC certified barrier facility at Florida International
University. All procedures were reviewed and approved by the Institutional Animal Care
and Use Committee at FIU and conducted in accordance with the National Academy of
Science Guide for Care and Use of Laboratory Animals. C57BL/6 Inpp4b-/- mice was
kindly provided by Dr. Vacher (Institut De Recherches Cliniques De Montreal, Canada),
and bred with FVB for at least three generations. Genotyping procedure was described in
original publication (28). Two month old male mice were euthanized, weighed, their
urogenital organs dissected and weighed, prior to RNA and protein extraction or
formaldehyde fixation and paraffin embedding. For short-term high-fat diet treatment, 6
weeks old WT or Inpp4b-/- males were fed with control chow (LabDiet 5V75, St. Louis,
MO) or high-fat diet (58% fat diet, TestDiet 58R3, St. Louis, MO) for one month before
euthanasia.
Immunohistochemistry (IHC)
Whole prostates were fixed in 4% formaldehyde (Electron Microscopy Sciences, Hatfield,
PA) overnight and embedded in paraffin. Sections (7 µm) were deparaffinized in xylene
and rehydrated in ethanol. Antigen was retrieved by heating slides in 0.01M sodium citrate
buffer (pH 6.0) (Fisher Scientific, Hampton, NH). Endogenous peroxidase was blocked by
1% hydrogen peroxide (Fisher Scientific) followed by incubation in 5% BSA for 45min.
Slides were incubated with primary antibodies for INPP4B (Santa Cruz Biotechnology) or
AR (Santa Cruz Biotechnology) at 1:800 dilution in TBS-T overnight. ABC kit (Vector
Laboratories, Burlingame, CA) and Peroxidase substrate kit (DAB) (Vector Laboratories)
were used to visualize the staining as suggested by manufacturer. Slides were rinsed with
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tap water and counterstained with hematoxylin (EMD Millipore). All images were acquired
by AxioCam camera and were processed by AxioVision LE software (Zeiss).
Statistical analysis
Comparisons of mean levels of expression of specific mRNAs and combination indices
(CI) were done as previously described (32). Student t-tests were used to test for inequality
of means from two independent samples. P-values less than 0.05 were considered to be
statistically significant. Values are present as mean ±SEM. All experiments were repeated
at least three times, unless stated otherwise. Biological triplicates were used for every point
in individual experiment for evaluating changes in gene expression in cell lines.
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CHAPTER 3: INPP4B PROTECTS FROM METABOLIC DISEASE AND
ASSOCIATED DISORDERS.
3.1.

Abstract

A high fat diet and obesity have been linked to the development of metabolic dysfunction
and the promotion of multiple cancers. The causative cellular signals are multifactorial and
not completely understood. In this report, we show that INPP4B signaling protects mice
from diet-induced metabolic dysfunction. INPP4B suppresses AKT and PKC signaling in
liver by dephosphorylating PI(3,4)P2 and PI(4,5)P2 respectively thereby improving insulin
sensitivity. INPP4B loss results in proteolytic cleavage and activation of the of key
regulator of de novo lipogenesis and lipid storage, SREBP1. Combined with the high fat
diet, SREBP1 increases expression and activity of PPARG and other lipogenic pathways,
leading to obesity and non-alcoholic fatty liver disease (NAFLD). Inpp4b-/- male mice fed
high fat diet had type II diabetes, expansion and inflammation of adipose tissue,
characteristic of metabolic dysfunction. In turn, systemic and localized inflammation
drives the development of high-grade prostatic intraepithelial neoplasia. Thus, INPP4B is
required for metabolic health and protects from metabolic disorder associated prostate
neoplasms.
3.2.

Introduction

In 2017, overconsumption and unhealthy diets contributed to 11 million deaths globally.
Diet associated deaths from cancers and diabetes were ranked second and third behind
cardiovascular disease (174). The National Center for Health Statistics reported in 2016
that over 80% of adult males aged 20 years and older were overweight or obese. Among
this age group, 70% of obese men and 30% of normal weight men will develop metabolic
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dysfunction (175).The consumption of a high-fat diet (HFD) is recognized as a leading
cause of obesity, metabolic dysfunction, elevated chronic inflammation (103) and cancer
mortality (104). Major indicators of metabolic dysfunction include elevated glucose levels,
insulin resistance, and the expansion of mesenteric and omental adipose tissues (176).
Importantly for men, an HFD and resulting obesity are tightly associated with lower urinary
tract syndromes, including benign prostatic hyperplasia (BPH) (177), accelerated
progression of prostate cancer; and decreased prostate cancer patient survival rates (178,
179).
Increasing evidence suggests that non-alcoholic fatty liver disease (NAFLD) is the best
clinical indicator of metabolic dysfunction in both obese and lean individuals (180, 181).
Hepatic lipid storage is a result of dysregulation of insulin signaling. Activation of the
insulin receptor in liver, muscle, and fat cells leads to the activation of PI3K/AKT signaling
pathways (182). High levels of circulating diacylglycerols (DAG) associated with HFD
activate PKC, which, in turn, phosphorylates and inhibits the insulin receptor, lowering
insulin sensitivity (106). In both mice and men, obesity elevates DAG levels and activates
PKC signaling in multiple tissues, leading to the development of NAFLD and insulin
resistance. Clinically, the levels of DAG and PKCε activation are the strongest predictors
of insulin resistance in obese men (183).
Importantly, an HFD is not exclusively responsible for metabolic syndrome since some
obese individuals maintain a healthy metabolic profile (106, 184, 185). There are a number
of variants in several genes that can modulate the effects of known determinants of
metabolic health. Polymorphisms in peroxisome proliferator-activated receptor γ
(PPARG), adiponectin (ADIPOQ), leptin receptor (LEPR), and insulin receptor substrate 2
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(IRS2) have been linked to obesity and type 2 diabetes mellitus (T2D) (186-189). However,
the specific signaling pathways that are disrupted during the initiation of metabolic
dysfunction are still not known.
INPP4B dephosphorylates both membrane lipids and phosphoproteins (32). We have
shown that INPP4B suppresses the AKT and PKC pathways (32, 53, 134), which are major
mediators of metabolic dysfunction, suggesting a role for INPP4B in the regulation of
metabolic health. We tested this hypothesis using Inpp4b-/- male mice to compare their
metabolic fitness to that of the wild type males. We found that INPP4B has diet-dependent
and independent actions in mouse liver, adipose tissue, pancreas, and prostate. When fed a
low-fat diet (LFD), three-month old Inpp4b-/- males developed liver steatosis associated
with hyperglycemia. When fed an HFD, in addition to liver steatosis, Inpp4b-/- males also
developed type II diabetes (T2D), inflammation of the visceral white adipose tissue (WAT)
and prostate, and PIN. Thus, the loss of INPP4B results in metabolic dysfunction by
increasing hepatic lipogenesis, elevating systemic and local inflammation, and promoting
the neoplastic transformation of the prostates in obese males.
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Figure 3-1. Inpp4b knockout accelerates adipose tissue expansion in mice on a high-fat diet. (a)
mRNA expression of INPP4B in mouse tissues. (b) Body weight of LFD WT (N = 14), LFD
Inpp4b-/- (N = 12), HFD WT (N = 9) and HFD Inpp4b-/- (N = 10) mice were recorded every week.
Weight of mammary gland (c) and epididymal adipose tissue (eWAT) (d) were compared in the
indicated groups at 12 weeks of age. (e) Protein lysates from eWAT were analyzed for FAS, HK2,
CD68, and tubulin using western blotting. (f) Quantification of FAS protein level from (e). The
FAS levels were normalized to tubulin and are shown as fold change.
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3.3.

Results

3.3.1. Accelerated weight gain in Inpp4b deficient male mice fed high fat diet.
Inpp4b expression was detected in multiple tissues (25). Analysis of mouse tissues showed
that the highest expression of Inpp4b is in the testis, mammary gland fat pad, epididymal
white adipose tissue (eWAT), muscle, and the ventral and dorsolateral lobes of the prostate.
Lower levels of Inpp4b mRNA were also detected in the pancreas and liver (Figure 3-1 a),
indicating that Inpp4b is expressed in major organs involved in insulin resistance. Inpp4b/-

males fed with an HFD gained significantly more weight than age-matched wild type

(WT) controls (Figure 3-1 b). At three months of age, obesity in Inpp4b-/- males was not
accompanied by changes in body length, blood pressure, or heart rate (Figure 3-2 a – c). A
comparison of two representative depots of visceral WAT, the #4 mammary fat pad, and
eWAT, revealed a significant weight increase in the HFD-fed Inpp4b-/- males versus the
WT males (Figure 3-1 c – d). In eWAT, neither diet nor Inpp4b knockout altered the protein
levels of HK2, an enzyme that mediates the commitment step of glycolysis (Figure 3-1 e,
Figure 3-2 d). Expression of fatty acid synthase (Fasn) mRNA was increased with HFD
(Figure 3-1 e) and the FASN protein levels were further increased in eWAT of HFD treated
Inpp4b-/- mice (Figure 3-1 e – f), suggesting a role for INPP4B in lipid accumulation.
Expression of Inpp4b was not affected in eWAT tissue by the HFD (Figure 3-2 f). Thus,
the loss of INPP4B combined with an HFD treatment activated lipogenesis and led to
significant adipose expansion.
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Figure 3-2. Morphometric and metabolic response to HFD and INPP4B loss. (a-c) Body length (a),
blood pressure (b), and heart rate (c) were measured for HFD WT (N = 9) and HFD Inpp4b-/- mice
(N = 10). (d-e) RNA was extracted from eWAT of LFD WT (N = 13), LFD Inpp4b-/- (N = 11),
HFD WT (N = 9), and HFD Inpp4b-/- (N = 10) mice and analyzed for Hk2 (d) and Fasn (e)
expression by qRT-PCR using 18S as an internal control. (f) The expression levels of Inpp4b in
eWAT were determined in LFD WT and HFD WT mice by qRT-PCR and normalized to 18S
expression. (g) Semi-quantification of levels of Leptin, Adiponectin, Leptin/Adiponectin, MCP-1,
IGFBP1, IGFBP2, and Lipocalin-2 in the eWAT of LFD WT, LFD Inpp4b-/-, HFD WT and HFD
Inpp4b-/- are presented as fold change of relative pixel density. Signal intensity in LFD WT mice
was designated as 1. Protein extracts from 5 mice were combined in each group and used for the
adipokine array.
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Figure 3-3. Inpp4b knockout accelerates inflammation in mice on a high-fat diet. (a-f) RNA was
extracted from mouse eWAT of LFD WT, LFD Inpp4b-/-, HFD WT, and HFD Inpp4b-/- mice. The
expression levels of Lep/Adipoq (a), Il6 (b), Tnf (c), Adgre1 (d), and Cd68 (e) were assayed by
qRT-PCR using 18S as an internal control. (l) Quantification of CD68 protein levels from Figure
3-1 e. Average expression in LFD WT mice was designated as 1. (*p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001)

3.3.2. High levels of inflammatory cytokines and expression of macrophage markers
in visceral fat of Inpp4b deficient male mice.
WAT secretes a broad variety of adipokines and cytokines that modulate inflammation and
insulin signaling (190-193). We tested whether INPP4B regulates the inflammatory status
of adipose tissue in HFD-fed males. Strikingly, the eWAT of HFD-fed Inpp4b-/- mice had
a significantly increased ratio of leptin to adiponectin expression (Figure 3-3 g) and
elevated expression of the inflammatory cytokines Il6 and Tnf (Figure 3-3 h – i). The
adipose tissue in HFD-fed knockout males showed an increased expression of the
macrophage markers Adgre1 and CD68 (Figure 3-3 j – k). The highest protein levels of
CD68 were observed in the eWAT of the HFD Inpp4b-/- group, suggesting that the INPP4B
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deficiency promotes the inflammatory response of adipose tissue in the diet-induced
obesity (Figure 3-3 l). As shown in Figure 3-3 g – l, both HFD and INPP4B loss contributed
to increases in inflammation and infiltration markers in the adipose tissue.
Using adipokine arrays, we compared the protein levels of 40 adipokines from the eWAT
of WT and Inpp4b-/- mice fed with LFD or HFD (Figure 3-2 g). The array analysis
confirmed the increased leptin/adiponectin ratio at the protein level. Consistent with the
increased presence of CD68+ cells, the eWAT from Inpp4b-/- mice expressed significantly
higher levels of the proinflammatory chemokine, monocyte chemoattractant protein – 1
(MCP-1), which promotes macrophage infiltration and is known to be increased in obese
diabetic mice (194, 195). Adipose expansion and inflammation are downregulated by
INPP4B in obese animals, suggesting a protective role for INPP4B from metabolic
syndrome.
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Figure 3-4. INPP4B protects mice from hyperglycemia and diabetes. (a) Oral glucose tolerance test
of LFD WT (N = 7), LFD Inpp4b-/- (N = 7), HFD WT (N = 9) and HFD Inpp4b-/- (N = 6) mice
following a 2 g/kg oral glucose challenge. Blood glucose levels were measured after 6 hours of
fasting (b) or in non-fasted (c) LFD WT, LFD Inpp4b-/- , HFD WT and HFD Inpp4b-/- mice. (d)
Blood insulin level was measured using mouse insulin ELISA in the indicated groups. (e) INPP4B
expression in livers of subjects with or without type II diabetes (T2D) were exported from
GSE15653. (f) Pancreas sections from LFD WT, LFD Inpp4b-/-, HFD WT and HFD Inpp4b-/- mice
were stained for insulin and counterstained with hematoxylin. (*p < 0.05, ***p < 0.001, ****p <
0.0001)
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3.3.3. Inpp4b deficient mice develop hyperglycemia on normal low fat diet and type
2 diabetes on high fat diet.
The expansion and increased inflammation of adipose tissue suggested that Inpp4b-/animals are insulin resistant. In fact, in an independently conducted QTL analysis in mice,
Mu et al. have shown an association between the D8Mit195 locus, mapped immediately
next to the Inpp4b gene, and elevated plasma glucose levels (LRS=10.4, LOD=2.3) (196).
The increase in the Lep/Adipoq ratio observed in HFD Inpp4b-/- group, is characteristic to
obese diabetic mice and men (197, 198). Glucose tolerance tests revealed that WT HFDfed mice had an elevated fasting blood glucose level compared to the lean WT males. Upon
administration of an oral glucose bolus to WT males, serum glucose levels rose higher in
HFD group than in LFD but recovered to normal after 120 minutes. When fed with either
LFD or HFD, Inpp4b-/- mice had elevated fasting glucose levels and they were unable to
fully clear it after 120 minutes (Figure 3-4 a – b). The rapid rise to extremely high fasting
glucose levels and the inability to clear blood glucose in obese Inpp4b-/- males were
consistent with obesity-induced T2D (199). Circulating, non-fasting glucose and insulin
levels were also significantly elevated in HFD-fed mutant animals compared to every other
group (Figure 3-4 c – d). Despite normal levels of circulating insulin in LFD Inpp4b-/males, the rate of hepatic gluconeogenesis was increased, confirming that lean knockout
males developed hyperglycemia (Figure 3-5 a). Similar to our HFD Inpp4b-/- male mice,
gene expression analysis in the livers of nondiabetic (N = 9) and T2D obese individuals (N
= 9) (GSE15653) revealed that INPP4B expression was decreased in the obese, diabetic
group (Figure 3-4 e) (200). As expected, pancreatic islets were positive for insulin staining
by IHC (Figure 3-4 f). Consistent with the increase in blood insulin levels, the expression

65

of proinsulin convertase, Pcsk1, was increased in the pancreata of LFD-fed Inpp4b-/- mice
and in both HFD-fed groups (Figure 3-5 b). Both HFD and Inpp4b knockout decreased
expression of the peptide hormone cholecystokinin (Cck), an appetite suppressant and
stimulant of pancreatic enzyme secretion (201) (Figure 3-5 c). The markers of pancreatic
β-cell viability and inflammation, Furin and Il6, and the unfolded protein response (UPR),
Mafa, did not significantly change (Figure 3-5 d – f) at 3 months of age. Our results and
results from other groups suggest that INPP4B is a metabolic modulator that protects from
diet induced T2D.

Figure 3-5. Development of hyperglycemia in LFD Inpp4b-/- males. (a) For the pyruvate tolerance
test, sodium pyruvate was injected intraperitoneally at 1.5 g/kg to age-matched LFD WT and LFD
Inpp4b-/- mice (N = 8 per group). (b-f) RNAs were extracted from mouse pancreas of LFD WT,
LFD Inpp4b-/-, HFD WT, and HFD Inpp4b-/- mice. The expression levels of Pcsk1 (b), Cck (c),
Furin (d), Il6 (e), and Mafa (f) were assayed by qRT-PCR. (*p < 0.05)
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3.3.4. Loss of INPP4B leads to NAFLD.
NAFLD is the best predictor of insulin resistance (180). To determine whether insulin
resistance in Inpp4b-/- mice is associated with NAFLD, we first compared the liver weights
in WT and Inpp4b-/- males fed LFD or HFD. Strikingly, the liver weights were significantly
elevated in Inpp4b-/- knockouts independent of the diet (LFD p = 0.0422, HFD p = 0.0374)
(Figure 3-6 a). Morphometric quantification of H&E stained slides revealed severe
steatosis in the livers of all Inpp4b-/- mice (LFD groups: p = 0.0111, HFD groups: p =
0.0004) (Figure 3-6 b – c). Livers in knockout animals featured all major histological
characteristics of NAFLD, such as accumulation of fat (Figure 3-6 d), microvesicular and
macrovesicular steatosis, hepatocellular hypertrophy, inflammatory cell aggregates,
pyknotic nuclei, and Mallory bodies (Figure 3-6 e) (202). Liver triglyceride amounts were
significantly increased in Inpp4b-/- mice compared to WT controls in both LFD (p =
0.0478) and HFD (p < 0.0001) groups (Figure 3-7 a). In the livers of WT FVB male mice,
the HFD caused modest increases in the expression of Inpp4b and Cd68, a marker of
infiltrating macrophages (Figure 3-7 b – c). In human liver, INPP4B was detected in the
cytoplasm and cell membrane of normal hepatocytes and its protein levels decreased in
primary and especially metastatic hepatocellular carcinoma (203) which undergo
significant metabolic reprogramming. Similar to the mouse liver, hepatic INPP4B
expression in patients with NAFLD was significantly reduced compared to healthy controls
(GSE126848) (204) and there was a highly significant correlation between steatosis score
and INPP4B mRNA levels (Figure 3-6 f – g). Thus, the loss of INPP4B in mice is similar
to the decline in INPP4B expression observed in steatotic livers of NAFLD patients (204).
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Figure 3-6. INPP4B protects mice from liver steatosis. Livers were dissected from LFD WT (N =
11), LFD Inpp4b-/- (N = 13), HFD WT (N = 9), and HFD Inpp4b-/- (N = 10) mice. (a) Liver weights
in four experimental groups. (b) Representative H&E staining of liver sections from designated
experimental groups used for steatosis analysis. (c) Morphometric quantification of the unstained
area on H&E stained liver sections. (d) Representative images of the Oil Red O/ hematoxylin
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staining of frozen liver sections in designated groups. (e) Characteristic features of hepatocellular
steatosis in livers of HFD and LFD Inpp4b-/- males. Examples of hypertrophy (open arrow),
inflammatory cell aggregates (dash line), Mallory bodies (arrowhead), macrovesicular steatosis
(red arrow), and microvesicular steatosis (black arrow) in LFD and HFD Inpp4b-/- mice. (f) INPP4B
expression in RPKM (Reads Per Kilobase Million) in normal liver tissue (N = 14), obese (N = 12
patients), and NAFLD (N = 15 patients) in GSE126848 dataset. (g) Correlation between INPP4B
expression with the steatosis score in patients with NAFLD or NASH. Data were exported from
GSE126848. (*p < 0.05, **p < 0.01, ***p < 0.001)

Figure 3-7. Aberrant lipid storage in livers of Inpp4b-/- males. (a) The amounts of total triglycerides
in liver were measured in LFD WT (N = 8), LFD Inpp4b-/- (N = 8), HFD WT (N = 6) and HFD
Inpp4b-/- (N = 4) mice. (b) RNAs were extracted from mouse livers and the expression level of
Inpp4b was determined in LFD WT and HFD WT mice using qRT-PCR and normalized to 18S.
The expression levels of Cd68 (c) and Ppara (d) were analyzed by qRT-PCR in groups with the
indicated diets and genotypes. (*p < 0.05, **p<0.01, ****p<0.0001)
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Figure 3-8. INPP4B regulates metabolic and PPAR pathways in mouse liver. (a) RNA were
extracted from livers of HFD WT (N=4) and HFD Inpp4b-/- (N=4) mice and were submitted for
RNA sequencing. The changes in gene expression were compared between HFD WT and HFD
Inpp4b-/- mice. (b) KEGG pathway functional enrichment analysis were done using DAVID
functional annotation module (top) or GSEA (bottom). The vertical axis represents the KEGG
pathway terms significantly enriched by the differentially expressed gene with the loss of INPP4B
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in mouse liver. The horizontal axis shows the logarithmic scale of p value. (c-i) RNA from LFD
WT (N = 10), LFD Inpp4b-/- (N = 12), HFD WT (N = 8), and HFD Inpp4b-/- (N = 10) mice were
analyzed for Pparg (c), Cd36 (d), Mogat1 (e), Vldlr (f), Cyp2b9 (g), Cyp2b13 (h), and Hao2 (i) by
qRT-PCR using 18S as an internal control. (j) Correlation between INPP4B expression and PPARG
expression in 289 human liver samples (GSE24335). (**p < 0.01, ***p < 0.001, ****p < 0.0001)

3.3.5. NAFLD in Inpp4b-/- males is caused by increased lipogenesis, WAT
inflammation, and activation of AKT and PKC signaling.
To determine the molecular pathways that protect WT mice on HFD from NAFLD, we
performed RNA-seq analysis of liver samples from WT and Inpp4b-/- males on an HFD.
Analysis of differentially expressed genes (DEG) with DAVID functional annotation
module and Gene Set Enrichment Analysis (GSEA) revealed that Inpp4b deletion affected
lipid and glucose metabolisms, drug detoxification, peroxisome biogenesis, and expression
of T2D associated genes (Figure 3-8 a – b). Lipid metabolism and peroxisome biogenesis
are known targets of the PPAR family of transcription factors (203, 205, 206). PPARG is
a transcriptional regulator of fatty acid uptake and storage, while PPARA activity
stimulates fatty acid oxidation. Expression of Pparg increased in both LFD and HFD-fed
Inpp4b-/- males compared to WT controls (Figure 3-8 c). Correspondingly, expression of
PPARG target genes regulating lipid delivery, internalization, triglyceride synthesis, and
fatty acid metabolism increased in Inpp4b-/- livers (Figure 3-8 d – g). Strikingly, a group of
genes involved in sexually dimorphic drug and lipid metabolism, Cyp2b9, Cyp2b13, Hao2
(GSE 89091) (207), were strongly downregulated by INPP4B and their expression strongly
increased in livers of knockout males (Figure 3-8 g – i). Ppara expression was modestly
increased in LFD Inpp4b-/- group only (Figure 3-7 d), potentially contributing to partial
NAFLD resistance in lean knockout animals. Similar to Inpp4b-/- mice, liver samples

71

Figure 3-9. INPP4B regulates lipogenesis and AKT and PKC signaling pathways in mouse liver.
(a) RNA from Figure 4(c-i) were analyzed for Srebf1 by qRT-PCR using 18S as control. (b)
Proteins were extracted from livers of LFD WT, LFD Inpp4b-/-, HFD WT, and HFD Inpp4b-/- mice
and used to compare levels of unprocessed SREBP1, processed SREBP1, and tubulin by Western
blotting. (c) Quantification of processed SREBP1 levels were presented as an average of four
independent samples. The protein levels were normalized to tubulin and were shown in fold change
from LFD WT. (d) Protein lysates from (b) were analyzed for pAKT, total AKT, pPKCβII, pPKCζ,
pPKCε, and tubulin using western blotting. (e-f) Quantification of pAKT and pPKCβII protein
levels from (d). (*p < 0.05, **p < 0.01, ***p < 0.001)
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collected in the course of Roux-en-Y gastric bypass surgery from 1008 obese patients
(GSE24335) exhibited a highly significant negative correlation between INPP4B and
PPARG expression (208) (Figure 3-8 j). Thus, expression data in mice and men support
our finding that INPP4B downregulates PPARG levels in liver. Disparate spatial
localization of these proteins suggests the existence of an intermediate regulatory protein.
SREBP1 is a transcriptional activator of many lipogenic enzymes, including Pparg (209,
210). Based on our RNA-seq analysis, the levels of Srebf1 mRNA did not significantly
increase in Inpp4b-/- livers (Figure 3-9 a). However, activation of SREBP1 requires
proteolytic cleavage and nuclear translocation (211, 212). Comparison of the precursor
(125 kDa) and transcriptionally active (55 kDa) forms of SREBP1, showed a significant
increase of the 55 kDa form due to both Inpp4b knockout and HFD treatment (Figure 3-9
b – c). SREBP1 proteolysis is induced by a variety of signals, including insulin, Akt,
retinoids, PKC, and its own activated form (211, 212). Thus, the activation of insulin,
retinol, Akt, and PKC signaling pathways in obese knockout males stimulates proteolytic
cleavage of SREBP1 in the livers of HFD Inpp4b-/- group activating expression of Pparg
and other lipogenic enzymes and leading to the development of hepatosteatosis.
3.3.6. HFD causes neoplastic changes in prostates of Inpp4b-/- mice.
Inpp4b-/- mice on regular chow have the same weight as the WT animals and do not develop
tumors in the first 4 months of age; some hyperplastic changes developed only in one year
old animals (54). The increased leptin/adiponectin ratios and adipose inflammation are risk
factors for the development of prostate cancer in men (213, 214) and were observed in in
HFD Inpp4b-/- males. We tested whether significant metabolic dysfunction triggered by the
HFD would lead to an earlier and more severe prostate phenotype in knockout male mice.
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Indeed, all Inpp4b-/- males (N = 11) developed high grade PIN by 11 weeks of age, while
none of the WT males on the same diet did. Anterior prostate (AP), dorsolateral prostate
(DLP), and ventral prostate (VP) lobes exhibited various degrees of epithelial expansion
and loss of polarity. The most extensive histological changes were observed in DLP glands,
including epithelial and basal layer expansion, piling up of epithelial cells, loss of polarity,
nuclear atypia, and a discontinuous fibromuscular layer around individual glands (Figure
3-10 a – b). Androgen receptor activity, cell signaling, and inflammation are among the
factors most strongly contributing to neoplastic transformation of the prostate (215). The
levels of AR and PTEN were not significantly altered by INPP4B loss on either diet. While
the HFD led to increased macrophage infiltration in the prostates of both WT and mutant
males, there was no difference between both genotypes in Cd68 expression (
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Figure 3-11 a – e). Consistently, inflammatory infiltrate was observed in the prostate
stromae

of

obese

WT

and
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knockout

males

(

Figure 3-11 f, marked with *). Staining with the Ki67 antibody indicated increased cellular
proliferation in the prostates of HFD Inpp4b-/- males (Figure 3-12 a). While AR protein
levels did not change, its transcriptional activity was affected. Expression of AR-induced
target genes, Pbsn, Apof, Nkx3.1, and Msmb, were significantly decreased in the DLP of
LFD Inpp4b-/- males (Figure 3-10 c - f). HFD further decreased expression of AR target
genes Nkx3.1 and Msmb (Figure 3-10 e – f). However, we observed no change in the ability
of AR to repress transcription of its target gene Igfbp3 (Figure 3-10 g). Levels of pAkt were
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increased in prostates of LFD Inpp4b-/- mice; no further increase was detected in HFDtreated groups (Figure 3-12 c – d). Similarly, levels of PKCβII and pPKCζ were slightly
increased in DLP and VP lobes of LFD Inpp4b-/- males and treatment with HFD did not
further increase the signal (data not shown).
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Figure 3-10. Loss of Inpp4b leads to the development of PIN and inflammation in obese males. (a)
H&E staining of prostates from LFD WT, LFD Inpp4b-/-, HFD WT, and HFD Inpp4b-/- males. (b)
Representative tissue sections from LFD WT, LFD Inpp4b-/-, HFD WT, and HFD Inpp4b-/prostates were stained for α-SMA and counterstained with hematoxylin. Anterior prostate (AP),
dorsolateral prostate (DLP) and ventral prostate (VP) were dissected from LFD WT, LFD Inpp4b/, HFD WT, and HFD Inpp4b-/- mice. (c-j) RNA was extracted and the expression levels of Pbsn
(c), Apof (d), Nkx3.1 (e), Msmb (f), Igfbp3 (g), Il6 (h), Tnf (i), and Il1b (j) were compared by qRTPCR using 18S as an internal control. (k) Protein levels of IL-6 in mouse dorsolateral prostates
were measured using IL-6 ELISA. (*p < 0.05, **p < 0.01, ***p < 0.001)

3.3.7. HFD leads to prostate inflammation in Inpp4b-/- males.
Inflammation plays a key role in the etiology of prostate cancer (216). We tested whether
the development of prostate neoplasms in the HFD Inpp4b-/- males was accompanied by
inflammation. In the dorsolateral lobe of the prostates of obese males, Il6 and Tnf mRNA
levels were significantly increased in Inpp4b-/- mice when compared to WT (Figure 3-10 h
– i). As expected, expression of the potent pro-inflammatory cytokine, Il1b, was
undetectable in the prostates of LFD mice. Consumption of HFD induced the expression
of Il1b in the prostates in both genotypes. Specifically, in the DLP, the loss of INPP4B
resulted in a significant increase in Il1b expression when compared to WT (Figure 3-10 j).
Protein levels of the proinflammatory cytokine IL6 were significantly increased in the DLP
of HFD fed Inpp4b-/- mice (Figure 3-10 k). While there are anatomical differences between
mice and humans, the mouse DLP is considered most similar to the human peripheral zone,
the site of origin of most human prostate cancers (217). It is also important to note that in
the prostate, the dorsolateral region features the highest expression of Inpp4b (Figure 3-12
b), suggesting a physiological function for INPP4B protein in that lobe.
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Figure 3-11. Prostate-specific levels of AR, PTEN and inflammation in WT and Inpp4b-/- males.
(a) Protein levels of AR, PTEN, and tubulin in AP, DLP, and VP of LFD WT, LFD Inpp4b-/-, HFD
WT and HFD Inpp4b-/- mice were assayed by western blotting. (b) Quantification of AR protein
levels were done using tissues from five individual mice in the indicated groups; representative
western blot is shown in (a). (c-e) RNAs were analyzed for Pten (c), Ar (d) and Cd68 (e) expression
by qRT-PCR and normalized to 18S. (f) H&E staining showed immune cell infiltration (labeled as
*) in the prostates of WT and knockout males fed with HFD. (**p < 0.01, ****p<0.0001)

80

Figure 3-12. Loss of INPP4B promotes proliferation in prostatic epithelial cells in obsess male
mice. (a) Representative prostate tissue sections from LFD WT, LFD Inpp4b-/-, HFD WT, and HFD
Inpp4b-/- prostates were stained for Ki67 and counterstained with hematoxylin. (b) RNAs were
analyzed for INPP4B expression in AP, DLP and VP of WT mice fed with LFD or HFD. (c) Protein
levels of pAkt, total Akt, and tubulin were assayed in indicated groups by western blotting. (d)
Quantification of protein levels of pAkt from the western blot in (c). The averages were calculated
from six individual mice. The protein levels were normalized to tubulin and shown as fold change.
(*p<0.05, **p<0.01)
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3.4.

Discussion

Metabolic dysfunction is the cause of significant morbidity and mortality due to diabetes,
cardiovascular abnormalities, and an increased risk of cancer-associated incidence and
mortality. Though epidemiological links between increased calorie consumption, cancer,
and diabetes are well established, less is known about the specific genes that protect some
obese individuals from metabolic dysfunction and neoplasia. In this report, we show that
INPP4B is required for metabolic health in lean male mice and protects obese mice from
diabetes and prostate neoplasia.
INPP4B has been shown to play a tumor suppressor role in prostate, breast, and other
cancers (29, 46, 129, 134), however, Inpp4b-/- mice do not develop malignancies (31).
Significant metabolic changes were detected in Inpp4b-/- males at three months of age and
these changes were exacerbated by HFD. Loss of INPP4B-dependent regulation of Akt and
PKC pathways led to accelerated weight gain in Inpp4b-/- males fed with HFD. Hepatic
Akt and PKC signaling is required for insulin sensitivity (106), thus we observed inefficient
glucose clearance in both LFD and HFD Inpp4b-/- animals (Figure 3-4). Inpp4b-/- mice
developed hyperglycemia on an LFD and T2D on an HFD. Direct hepatic insulin action
and activated Akt and PKC signaling induce proteolytic cleavage of the SREBP1 precursor
protein into a mature transcription factor (211, 212) which regulates expression of Pparg
and other lipogenic enzymes. Consistently, we found that INPP4B loss and HFD
cooperatively induced SREBP1 cleavage and increased expression of Pparg and other
lipogenic transcripts (Figure 3-8). As a direct result of these transcriptional changes, we
observed the development of hepatosteatosis, WAT expansion and inflammation in
Inpp4b-/- males which were exacerbated by HFD. It is important to note, that the Inpp4b-/-
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mouse model closely models human NAFLD, as there was downregulation of hepatic
INPP4B expression in people with T2D and advanced hepatosteatosis, and a highly
significant negative correlation between the expression of INPP4B and PPARG in human
livers (Figure 3-6 f – g, and Figure 3-8 j).

Figure 3-13. Physiological functions of INPP4B in liver, WAT, and prostate. The loss of INPP4B
activates SREBP1, stimulates hepatic expression of Pparg, causing liver steatosis, insulin
resistance, de novo lipogenesis (DNL), and an increased rate of gluconeogenesis. When consuming
a HFD, the Inpp4b-/- males developed type 2 diabetes, inflammation and macrophage (MØ)
infiltration of WAT, DNL and an increased Leptin/Adiponectin ratio, all of which were shown to
stimulate the development of PIN. Consumption of an HFD promoted macrophage infiltration in
prostates of both WT and Inpp4b-/- mice; however, increased production of proinflammatory
cytokines was only evident in dorsolateral lobes of prostates of Inpp4b-/- mice.
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Metabolic dysfunction and adipose inflammation in HFD Inpp4b-/- males affected the
prostate gland development as is often observed in men with this condition. HFD Inpp4b/-

males were significantly more susceptible to obesity-induced neoplastic transformation

of the prostate than the WT males (Figure 3-10 a – b). Circulating leptin, pro-inflammatory
cytokines and locally activated immune cells likely contribute to the inflammatory
environment of the prostate (218-220). Similar to our HFD Inpp4b-/- mouse model, IL6 is
elevated in the serum of patients with metastatic PCa (221) and IL1β levels are increased
in both the tumors and serum of prostate cancer patients and correlates with disease severity
(222).
In summary, we discovered a novel function of INPP4B. We showed that INPP4B is an
essential regulator of metabolic health. It protects the liver from steatosis, mediates insulin
sensitivity and links obesity with neoplastic changes in the prostate epithelium. As shown
in Figure 3-13, Inpp4b deficient animals developed hyperglycemia on normal chow and
T2D on HFD by decreasing insulin sensitivity. Loss of INPP4B induced activation of
hepatic SREBP1 leading to an increased expression of Pparg and other genes involved in
lipogenesis. This ultimately caused NAFLD. Similar to men, the loss of INPP4B in HFD
fed mice also promoted obesity-induced WAT inflammation and prostate neoplasia. In
both mice and men, decline in hepatic INPP4B expression correlates with increasing levels
of NAFLD. Thus, Inpp4b-/- males faithfully reproduce complex metabolic syndrome in
men and INPP4B signaling cascade should be considered for therapeutic intervention in
this wide-spread disease.
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3.5.

Materials and Methods

Animal studies
Inpp4b-/- mice were described previously (28, 54). WT and Inpp4b-/- males were fed with
either LFD (LabDiet 5V75, St. Louis, MO) or HFD (TestDiet 58R3, St. Louis, MO). The
HFD consisted of 59.4% fat, 25.7% carbohydrate, and 14.9% protein (total 22.8 kJ/g),
whereas the regular chow contained 12.9% fat, 63.8% carbohydrate, and 23.2% protein
(total 13.6 kJ/g). LFD groups were continuously maintained on LFD. For HFD cohorts,
dams were fed the designated diet for 1 month prior to mating, during pregnancy, and 3
weeks’ lactation. Male pups were maintained on the HFD until euthanasia. Mouse body
weights were measured once a week. All LFD WT, LFD Inpp4b-/-, HFD WT, and HFD
Inpp4b-/- mice were euthanized and dissected at 12 weeks and their tissues where collected
for analysis. All protocols were approved by Florida International University Institutional
Animal Care and Use Committee.
Hemodynamic Measurements
Eleven–week-old HFD, WT, and Inpp4b-/- mice were anesthetized with 2% isoflurane in
100% oxygen. Each mouse was placed on a heating platform with the temperature around
38-40°C. A tail cuff connected to the pressurizing tubing was placed at the base of the
mouse tail and attached to the CODA monitor (Kent Scientific, Torrington, CT). The heart
rate, systolic blood pressure, diastolic blood pressure, and mean blood pressure where
recorded using a non-invasive blood pressure system.
Gene expression analysis
RNA was isolated from tissues using Tri Reagent (Molecular Research Center, Cincinnati,
OH) and reverse transcribed using a Verso cDNA synthesis Kit (Thermo Fisher Scientific).
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The quantitative real time PCR was performed using primers and probes listed in Table 7
using a Roche 480 LightCycler (Roche). For gene expression analysis, samples were from
LFD WT (N = 12), LFD Inpp4b-/- (N = 11), HFD WT (N = 9) and HFD Inpp4b-/- (N = 11)
mice.
Table 7. Primers and corresponding probes used in CHAPTER 3.
Mouse gene primers and corresponding probe sets
Gene
Forward primers
reverse primers
Ar
ccagtcccaattgtgtcaaa
tccctggtactgtccaaacg
Inpp4b
acagcaccagaaagtctgagc
ctttctgacatctgctcacgga
Apof
tctcaatggccggactgtat
aggatgagtcggaggctatg
Nkx3.1
cgactgaacccgagtctgat
aatcacctgagtgtgagagaagg
Msmb
cgtggtgttcatgtgacaaaa
ctcaaaggcctagtagcgttg
Pten
aggcacaagaggccctagat
ctgactgggaattgtgactcc
Probasin
tcatcctcctgctcacactg
gctaagtaaattgtttgccaagg
Pparg
ctctcagctgttcgccaag
cacgtgctctgtgacgatct
Adgre1
tgtcctccttgcctggac
gagacttctgagctgacactgc
Cd68
tccactgttggccctcac
ccccttggaccttggacta
Fasn
ttgctgaggacttcccaaac
gcgtcgatgctgtagactgt
Hk2
tgccaagcgtctccataag
aggaagcggacatcacaatc
Lep
cccaaaatgtgctgcagatag
ccagcagatggaggaggtc
Adipoq
ccatctggaggtgggagac
ctgcatagagtccattgtggtc
Il6
gctaccaaactggatataatcagga
ccaggtagctatggtactccagaa
Tnf
ttgtcttaataacgctgatttggt
gggagcagaggttcagtgat
Il1b
caggcaggcagtatcactca
tgtcctcatcctggaaggtc
Cck
cccagccatagaataagtgacc
attcgtagtcctcggcactg
Pcsk1
tccaaagttggaggcataaga
gaactagcctcaatggcatca
Gys1
ctgtcctgttcggcttcct
ccacatacggcttctcttcg
Furin
atgaatgacaacaggcatgg
cgggcattgtaagctacacc
Mafa
ctccagagccaggtggag
gtacaggtcccgctccttg
Tgfb1
tggagcaacatgtggaactc
cttggtaaccggctgctg
Col1a1
cctggacctcagggtattgctggacaac
aaggtccttctggatcaagtggt
Acta2
accacccacccagagtg
gctatgtgtgaagaggaagac
Insr
tctttcttcaggaagctacatctg
tgtccaaggcataaaaagaatagtt
Cd36
tggccttacttgggattgg
ggatttgcaagcacaatatgaa
Cyp2b13
gctgaggatggagaaggaga
tccagcaaagaagagagagagc
Cyp2b9
ggagaagtcaaaccacaacaca
gcaaagaagagagagagcacaga
Hao2
gaggcctccattggttcc
ccatctgcttgttgatgtcc
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Probe
58
89
17
5
62
60
47
50
29
10
17
75
80
1
6
64
76
42
42
72
74
10
72
72
20
91
9
9
9
71

Igfbp3
Mogat1
Ppara
Srebf1
Vldlr

gcagcctaagcacctacctc
ttcaatgggagtagccttgc
ggcttctttcggcgaactat
ggttttgaacgacatcgaaga
atggcatccgagactgtgtt

tcctcctcggactcactgat
gcattatgccaaagtagtgctg
cttgcagctccgatcacac
cgggaagtcactgtcttggt
gcactgattgacgtttttgc

1
6
41
78
21

Glucose tolerance test (GTT) and Pyruvate tolerance test (PTT)
The glucose tolerance tests were performed on 11-week-old males as previously described
(223). Briefly, after 6 hours of fasting, mice (n ≥ 8) were weighed and given 2 g/kg of
glucose (Sigma) through a gavage needle (18G, 5.08cm; Cadence Science, Cranston, RI).
A drop of blood was sampled from each mouse at 0, 15, 30, 60, 90, and 120 minutes after
oral gavage and the glucose concentration was determined immediately using the ACCUCHEK Nano SmartView glucometer (Roche Diagnostics, Indianapolis, IN). For pyruvate
tolerance testing, mice were fasted overnight, followed by intraperitoneal injection of
pyruvate (1.5 g/kg, Sigma-Aldrich, ST. Louis, MO). The blood glucose levels were
measured as above.
ELISA and adipokine array
Blood insulin levels were determined using the Ultra Sensitive Mouse Insulin ELISA Kit
(Crystal Chem, Elk Grove Village, IL); the manufacturer’s instructions were followed.
Briefly, 5 µl of blood serum from LFD WT (N = 23), LFD Inpp4b-/- (N = 20), HFD WT
(N = 9), and HFD Inpp4b-/- (N = 9) mice were used for the test. The insulin concentrations
were measured using CLARIOstar plate reader (BMG Labtech, Cary, NC). A Mouse IL6
ELISA kit (Sigma-Aldrich) was used to determine the IL6 level in LFD WT (N = 6), LFD
Inpp4b-/- (N = 10), HFD WT (N = 5), and HFD Inpp4b-/- (N = 5) mouse dorsolateral
prostates. Adipokines and proinflammatory cytokines were detected in WAT protein

87

extracts using the Proteome Profiler Mouse Adipokine Array Kit (R&D Systems,
Minneapolis, MN). Five samples from mice in each group were pooled and used for
analysis. The signal was captured using an ImageQuant LAS 500 imager (GE Healthcare,
Chicago, Illinois).
Morphometric quantification of steatosis
The steatosis was evaluated by measuring the surface of the unstained areas per field using
40X magnification. Five mice were selected from each group and 10 different areas from
each mouse were counted using ImageJ software (NIH).
Oil red O staining
Fresh liver tissue was placed in OCT medium and snapped frozen in liquid nitrogen. Liver
samples were cut at 12 μm sections and attached to glass slides. Oil red O was dissolved
in hot propylene glycol and filtered through Whatman #2 filter paper. Slides were fixed in
4% PFA, rinsed in distilled water and in propylene glycol, stained in oil red O, and
counterstained with hematoxylin. All images were acquired using an AxioCam MRc5
camera (Zeiss, Thornwood, NY).
Determination of triglycerides in mouse liver
The total triglycerides in liver were measured in LFD WT (N = 8), LFD Inpp4b-/- (N = 8),
HFD WT (N = 6) and HFD Inpp4b-/- (N = 4) mice using a Triglyceride Colorimetric Assay
Kit (Cayman Chemical, Ann Arbor, MI). The assay was performed according to the
manufacturer’s instruction. The total amount of triglyceride in liver were calculated.
RNA sequencing and data analysis
RNA was purified as described above from HFD WT (N=4) and HFD Inpp4b-/- (N = 4)
and submitted to Novogene for RNA sequencing. The libraries were generated using the
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NEBNext® Ultra™ RNA Library Prep Kit and used for Illumina 150-bp paired-end
sequencing. Quality control assessment was done using Illumina RNA-seq pipeline to
estimate genomic coverage, percent alignment and nucleotide quality. Raw reads were
mapped to the reference mouse genome (the most recent build GRCm38) using HISAT2
(224) and STAR (225) software. For the differential analysis of known genes, the reads for
each gene aligned by HISAT2 were counted using HTSeq software (226). Alignment by
STAR was run with the option “quantMode TranscriptomeSAM” that allowed counting of
reads aligned to each gene. Raw counts from HTSeq and STAR were imported into
Bioconductor/R package DESeq2 (227), normalized and tested for differential gene
expression. This analysis was done separately for the files produced by each aligner. In
each analysis we selected genes that were expressed differentially based on the criteria of
False Discovery Rate (FDR) less than 10% and Fold Change more than 1.3 to either
direction. Data has been uploaded to NCBI's Sequence Read Archive (SRA) database with
accession number GSE134466. Genes that showed differential expression after analysis of
the files from both aligners have been selected for further analysis.
Pathway analysis and Gene Ontology (GO) analysis
Biological processes and pathways affected by INPP4B knockout in mouse liver, we
performed

using

Gene

Set

Enrichment

http://www.broad.mit.edu/gsea/index.html)

and

David

Analysis
bioinformatics

(GSEA,
functional

annotation analysis with differentially expressed genes obtained from the RNA-seq
analysis. The gene sets for KEGG pathways (c2 KEGG curated) and GO analysis (c5
curated)

were

acquired

from

Molecular

Signatures

Database

(http://software.broadinstitute.org/gsea/msigdb/index.jsp). All pathways and Go biological
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functions that are significantly affected by INPP4B were listed in Appendix. The
normalized enrichment score (NES) with FDR less than 25% or p value less than 0.05 were
considered significant (170).
Immunohistochemistry
The preparation of tissue sections for H&E and immunohistochemical staining were done
as previously described (54). Briefly, 5 µM sections were deparaffinized and antigen
retrieval was done by heating slides at 99°C for 15 minutes in 10 mM citrate buffer, pH=6.
Sections were blocked in 1% H2O2 in water and 5% BSA in PBS. Primary antibodies were
diluted in PBS at 1:6000 for α-SMA (#ab5694, AbCam, Cambridge, MA), 1:60,000 for
insulin (#ab181547, AbCam), and 1:200 in Ki67 (#RB-1510-P1, Thermo Fisher).
Antibodies were incubated overnight at 4°C or an hour at room temperature. Sections were
washed and incubated with biotinylated anti-rabbit secondary antibody for 18 minutes,
followed by incubation with streptavidin conjugated peroxidase for 30 minutes using the
Vectastain ABC Kit (Vector Laboratories, Burlingame, CA). The staining was developed
using the ImmPACT DAB Peroxidase Substrate Kit (Vector Labs, Burlingame, CA) and
the slides were counterstained with hematoxylin.
Western blotting
Mouse tissues were homogenized with a glass grinder in ice-cold RIPA buffer with
protease and phosphatase inhibitors. Cleared lysates were diluted to 4 µg/µl and 15-30 µg
of protein was resolved on a 7.5% - 10% SDS-PAGE. The sources and dilutions of
antibodies are listed in Table 8. The signal was captured using an ImageQuant LAS 500
imager and analyzed by ImageQuant TL software (GE Healthcare).
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Table 8. Antibodies used in CHAPTER 3.
Antibody

cat #

concentration

RRID

phospho-Akt S473

Cell signaling #4051

1:1000

AB_331158

Total Akt

Cell signaling #4691

1:1000

phospho-PKCζ T410

Cell signaling #2060

1:1000

phospho-PKCβII S660

Cell signaling #9371

1:1000

FAS

Cell signaling #3180

1:1000

HK2

Cell signaling #2867

1:1000

β-Tubulin

Millipore #05-661

1:5000

PTEN

Cell signaling #9188

1:1000

AR

Millipore #06-680

1:1000

PPARγ

Cell signaling #2443

1:1000

Ki67

Thermo Fisher RB-1510-P1

1:200

SREBP1

Novus NB 600-582

1:1000

AB_915783
AB_561487
AB_2168219
AB_2100796
AB_2232946
AB_309885
AB_2253290
AB_310214
AB_823598
AB_60160
AB_531394

CD68

Abcam ab125212

1:800

AB_10975465

PR

Homemade

1:1500

N/A

Statistics
All data are presented as mean ± SEM. Two-way ANOVA was performed by Prism 7.0.
P-values less than 0.05 were considered statistically significant.
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CHAPTER 4: INPP4B IS ESSENTIAL FOR MAMMARY GLAND BRANCHING
AND PROTECTS FROM NAFLD
4.1.

Introduction

The hormones estrogen and progesterone are produced by the ovaries and regulates the
development and physiology of the mammary gland (228). The corresponding liganddependent transcription factors, estrogen receptor-alpha (ERα) and progesterone receptor
(PR) are expressed in approximately 30% of luminal cells within the mammary gland
(229). Currently, more than 70% of breast cancers express ERα and their growth is ERα –
dependent (82). ERα functions as a ligand-activated transcription factor that regulates a
variety of genes that govern cell proliferation and survival in cancerous and non-cancerous
breast epithelial cells (83). Therefore, endocrine therapies that suppress the tumorproliferating effects of estrogen via interactions with ERα are a standard-of-care therapy.
However, many patients develop resistance that leads to lethal metastatic disease. Many
factors promote the development of aggressive breast cancer, including growth factors and
kinase signaling pathways such as PI3K/AKT and p44/42 MAPK that phosphorylate and
activate ERα independently of ligand (84-86).
Accumulating evidence demonstrates that overweight or obese individuals have an
increased risk of developing postmenopausal breast cancer (230-233). Post-menopausal
breast cancer patients frequently experience weight gain and worsened survival rates (234,
235). Similarly, the depletion of estrogens via an ovariectomy in female rodents leads to
weight gain and metabolic disorders, including adipose dysfunction and changes in glucose
metabolism (76, 236, 237). Many patients with metabolic disorders develop hepatic insulin
resistance and non-alcoholic fatty liver disease (NAFLD) characterized by increased
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triglyceride accumulation in the liver. Metabolic activity is regulated by multiple signaling
pathways, main among them are INSR/AKT and the PKC signaling pathways. The insulinstimulated uptake of glucose activates the AKT pathway, whereas circulating lipids
activate PLC/PKC pathways, which in turn stimulate hepatic lipid synthesis (PKCζ and
ι/λ) (238, 239).
Inositol polyphosphate 4-phosphatase type II (INPP4B) is a tumor suppressor and a dualspecificity phosphatase that dephosphorylates both lipid and phosphoprotein substrates,
similar to the tumor suppressor PTEN (32). Several groups have shown that INPP4B
functions as a tumor suppressor in various cancers including breast, ovary, thyroid, and
prostate malignancies by inhibiting AKT signaling (29, 31, 134). We have previously
shown that INPP4B also suppresses the PKC pathway (54, 134). In this dissertation
research, our group has demonstrated that Inpp4b deficiency in male mice leads to the
development of steatotic liver. In mice fed a high-fat diet (HFD), the presence of INPP4B
protects male mice from weight gain, insulin resistance, and type 2 diabetes.
In this study, we investigated the role of INPP4B in normal female physiology and
development and its role in the development of mammary gland cancers. Our data suggests
that INPP4B regulates ERα transcriptional activity using a different mechanism than
PTEN. Unlike PTEN, INPP4B knockdown significantly reduced the level of PR to below
the threshold required for lobuloalveolar development in the mammary gland (240).
Consistently, Inpp4b loss nearly abolished lateral branching in the mouse mammary gland
at the age of 12 weeks. These results are consistent with observations made in the PR
knockout mouse model. When fed an HFD, female Inpp4b-/- mice gained approximately
50% more weight than their wild type counterparts. Inpp4b loss led to an increase in white
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adipose tissue weight and the development of hyperglycemia. Moreover, the HFD Inpp4b/-

female mice developed steatotic livers and exhibited the early stages of fibrotic disease.

Further analysis of HFD fed Inpp4b-/- females revealed hyperplasia in the mammary end
buds and an expansion of extracellular matrix (ECM) which plays an important role in both
mammary gland development and tumorigenesis.
4.2.

Results

4.2.1. INPP4B is positively correlated with ESR1 in human breast cancer.
INPP4B is expressed in ERα-and Her2-positive breast cancers but it is lost in nearly all
triple-negative breast cancers (46, 99). We compared the correlation between the
expression of INPP4B and the ERα encoding gene, ESR1, in 1100 tumor samples from
women with invasive breast carcinoma. The expression of INPP4B was positively
correlated with ESR1 expression and retained a high Pearson’s rank correlation coefficient
(Figure 4-1 a, r = 0.6718). When ESR1 expression levels in individuals with altered
INPP4B expression were exported, ESR1 was highly expressed when INPP4B expression
was also high (Figure 4-1 b). The protein expression of INPP4B and ERα were acquired
from 892 tumor samples using RPPA and the data were exported from cBioportal
(https://www.cbioportal.org/). The INPP4B protein levels were positively correlated with
ERα protein levels in human breast tumors (Figure 4-1 c). The expression of PTEN, another
dual-specificity phosphatase, displayed a significantly weaker correlation with ESR1
(Figure 4-1 d, r = 0.2739). The ESR1 levels were not significantly affected by the alteration
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Figure 4-1. A positive correlation between INPP4B and ERα in human breast tissue samples. (a)
Correlation between INPP4B expression and ESR1 expression in 1100 breast adenocarcinoma
samples (TCGA, Provisional). (b) The corresponding mRNA level of ESR1 in samples expressing
low or high levels of INPP4B. Samples were considered altered if their INPP4B expression levels
were higher or lower than two standard deviations of the mean of all samples. (c) Correlation
between INPP4B protein level and ERα protein level in 892 breast cancer samples (TCGA,
Provisional). (d) Correlation between PTEN mRNA level and ESR1 mRNA level in samples
described in (a). (e) The corresponding mRNA level of PTEN and ESR1 in samples expressing low
or high PTEN levels. (f) Correlation between protein level of PTEN and ERα in samples described
in (c).
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of PTEN expression (Figure 4-1 e) and only a very weak correlation between PTEN and
ERα protein levels was observed in breast cancer samples (Figure 4-1 f).
4.2.2. INPP4B and PTEN depletion both modulate ERα transcriptional activity.
To compare the regulation of ERα protein expression and transcriptional activity by
INPP4B and PTEN, we performed an Affymetrix microarray using MCF7 cells that
expresses functional ERα, INPP4B, and PTEN. We used specific siRNAs to knockdown
INPP4B or PTEN and then exposed them to 1 nM E2 to activate ERα transcriptional
activity. Depletion of INPP4B nor PTEN had an effect on ESR1 expression (Figure 4-2 ac). Using Gene Set Enrichment Analysis (GSEA), we investigated whether ERα
transcriptional activity was affected by the loss of either INPP4B or PTEN. An ERα
signature with a total of 467 ERα regulated genes in the MCF7 cell line was generated from
GSE8597. The GSEA indicated that a subset of ERα target genes was significantly
enriched among INPP4B regulated genes (Normalized Enrichment Score (NES)=2.32, p
value<0.001), and to a lesser extent among

PTEN regulated genes (NES=1.76, p

value<0.01) (Figure 4-2 d-f), suggesting that both tumor suppressors modulate ERα
transcriptional output.
A comparison of the differentially regulated genes (DEG) affected by INPP4B or PTEN
knockdown revealed common and specific regulation of genes by INPP4B and PTEN
(Figure 4-3 a). We selected DEGs from the INPP4B knockdown samples and compared
the expression of these genes to that in PTEN knockdown samples. As seen in Figure 4-2
f, many genes were affected by the loss of INPP4B but were unaltered by the PTEN
knockdown. The list of genes that were preferentially up- or down-regulated by INPP4B
or PTEN were exported and can be found in Figure 4-3 b-c. Using GSEA, we analyzed the
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Figure 4-2. Both INPP4B and PTEN affect ERα transcriptional activity. (a-c) INPP4B and PTEN
were knocked down using specific INPP4B siRNA (IN KD) and PTEN siRNA (PT KD) in MCF7
cells for 48 hours. The expression level of INPP4B (a), PTEN (b), and ESR1 (c) were determined
by RT-qPCR using 18S as a control. (d-e) GSEA of INPP4B (d) and PTEN (e) affected genes using
ERα regulated gene as signature (GSE8597). (f) Forty-eight hours after INPP4B or PTEN
knockdown, we treated MCF7 cells with 1 nM vehicle or E2 for 12 hours. RNA was extracted and
used in the gene expression array. Comparison of the expression levels for differentially expressed
genes (DEG) from INPP4B knockdown samples and PTEN knockdown samples. (g-h) KEGG
functional enrichment analyses were done using GSEA. KEGG pathways were significantly
enriched by differentially expressed gene caused by INPP4B knockdown (g) or PTEN knockdown
(h). P-value was calculated and presented in logarithmic scale.
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DEG in INPP4B or PTEN knockdown samples and applied the signatures from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway database. As seen from Figure 4-2
g-h, INPP4B and PTEN depletion both affected immune system and p53 signaling
pathways. However, different from PTEN, INPP4B affected genes were also involved in
the IGF pathway, apoptosis and the MAPK cascade suggesting a divergent pattern of gene
regulation by INPP4B and PTEN in MCF7 cells (Figure 4-2 g-h).

Figure 4-3. Comparison between INPP4B and PTEN affected genes. (a) Venn diagram of
differentially expressed genes after INPP4B knockdown, PTEN knockdown and genes regulated
by ERα. (b-c) Heat map of the most up-/down-regulated genes after INPP4B knockdown (b) or
PTEN knockdown (c) in MCF7 cells.
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4.2.3. Differential expression of INPP4B and PTEN regulated genes in breast cancer
cells.
The representative genes that were preferentially affected by INPP4B or PTEN knockdown
were selected based on the microarray data and changes in their expression levels were
validated in MCF7 cells. We found that transcripts for PTPMT1 and CHD5 were
upregulated and HERC5 transcripts were downregulated in a similar fashion by both
INPP4B and PTEN knockdown (Figure 4-4 a).

INPP4B knockdown specifically

upregulated transcription of MT2A, while PTEN loss specifically upregulated CALU, a
potential marker of breast cancer progression (241) that was induced in murine Her2
overexpressing breast tumors (242). The downregulation of MYOF was significantly
stronger when INPP4B was knocked down compared to PTEN knockdown (Figure 4-4 b).
We next investigated whether INPP4B and PTEN differentially modulate ERα-dependent
gene expression. We selected representative estradiol (E2) induced genes and compared
their expression levels following INPP4B or PTEN knockdown. As seen in Figure 4-4 c-i,
all selected genes were significantly induced by E2. Depletion of either INPP4B or PTEN
increased ERα-induced transcription of early growth response 3 (EGR3) (Figure 4-4 c).
The ERα-induced SGK3, PGR, and UGT2B17 genes required both INPP4B and PTEN for
their optimal expression (Figure 4-4 d-f). Even though both INPP4B and PTEN stimulated
expression of MSMB, only the loss of PTEN essentially abolished MSMB expression
(Figure 4-4 g). Conversely, two ERα-dependent genes, CYP24A1 and RAPGEFL, were
regulated specifically by INPP4B in MCF7 cells (Figure 4-4 h-i).
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Figure 4-4. Differential gene expression patterns for INPP4B and PTEN. (a-b) RNAs from Figure
2 (a-c) were analyzed for PTPMT1, CHD5, HERC5, MT2A, MYOF, and CALU expression by RTqPCR using 18S as control. (c-i) MCF7 cells were transfected with INPP4B or PTEN siRNA for
48 hours and treated with E2 for another 24 hours before harvest. Gene expression of EGR3 (c),
SGK3 (d), PGR (e), UGT2B17 (f), MSMB (g), CYP24A1 (h), and RAPGEFL1 (i) as analyzed by
RT-qPCR.
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4.2.4. INPP4B is required for optimal expression of progesterone receptor (PR)
PR is required for mammary gland morphogenesis and is a biomarker for breast cancer
progression (243). INPP4B is required for both basal and E2 dependent expression of PGR,
the PR encoding gene (Figure 4-4 e). Consistently, forty-eight hours after INPP4B
knockdown, protein levels of both PR isoforms, PRA and PRB, were significantly reduced
in the independently derived MCF7 and T47D cell lines (Figure 4-5 a-c). In tumors from
529 women with invasive carcinoma of the breast, we observed a positive and highly
significant correlation between INPP4B and PGR on both RNA and protein levels (TCGA
Provisional) (Figure 4-5 d-f).
4.2.5. INPP4B is essential for ductal branching in the mouse mammary gland
Using a previously described Inpp4b knockout (Inpp4b-/-) mouse model (28, 54), we
investigated the role of INPP4B in non-malignant mouse mammary gland. The level of
estrogen fluctuates during the estrous cycle and stimulates the turnover of ERα and PR
(244). The murine estrous cycle includes four stages, proestrus, estrus, metestrus, and
diestrus (245). The diestrus stage has a relatively high level of both PR and ERα, when
compared to other stages (244). We chose this stage to study the role of INPP4B in mouse
mammary gland development. Both estrogen and progesterone signaling are required for
the development of the mammary gland. During puberty ER signaling stimulates the
expansion of the duct into the mammary gland fat pad (246), while epithelial PR is required
for ductal branching in adulthood (228). Therefore, we examined the mammary gland from
WT or Inpp4b-/- female mice at 11 weeks old. Inpp4b-/- females expressed similar levels of
Esr1 mRNA compared to WT controls, however a reduction in Pgr mRNA occurred in the
mammary gland of Inpp4b-/- females (Figure 4-6 a-b).
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Figure 4-5. INPP4B is required for optimal induction of PR. (a-b) INPP4B and PTEN were knocked
down using INPP4B or PTEN specific siRNAs in MCF7 or T47D cells in media supplemented
with 10% FBS for 48 hours. The protein levels of INPP4B, PTEN, PR, and tubulin were compared
by Western blotting in MCF7 cells (a) and T47D cells (b). (c) Quantification of PR level in MCF7
cell from four independent experiments. (d-f) Gene expression data was exported from the same
source as Figure 1. (d) Correlation between INPP4B and PGR expression in breast adenocarcinoma
samples. (e) The mRNA level of PR in samples expressing low or high INPP4B levels. (f)
Correlation between INPP4B protein level and PR protein level in 892 breast cancer samples.
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Using whole mounts, we assessed the ductal branching in WT and Inpp4b-/- females. At 11
weeks old, the mammary glands of WT female mice were fully arborized while the
mammary glands from Inpp4b-/- females displayed significantly reduced side branching
(Figure 4-6 c). The expression of amphiregulin, an ERα and PR regulated gene required
for mammary gland development (247, 248), was strikingly reduced in the mammary tissue
of knockout females (Figure 4-6 d).
4.2.6. INPP4B loss caused weight gain and hyperglycemia in mice fed with an HFD
We and others have previously shown that INPP4B suppresses the AKT and PKC pathways
in multiple cell lines (46, 54). We confirmed that INPP4B knockdown activated AKT and
PKC signaling in MCF7 cells (Figure 4-7 a-c). In the female mouse model, we showed
Inpp4b knockout activated PKC pathway in mouse mammary glands (Figure 4-7 d). Both
the AKT and PKC signaling pathways are conduits for insulin signaling and are associated
with metabolic disorders. Therefore, we investigated the role of INPP4B in the dietinduced model of obesity.
The Inpp4b-/- female mice fed HFD had a 50% increase in body weight compared to the
age-matched HFD WT mice (Figure 4-8 a). The weights of the visceral white adipose tissue
(WAT) and #4 mammary gland in HFD Inpp4b-/- female mice were significantly increased
when compared to the other three groups (Figure 4-8 b-c), suggesting that weight gain was
due to increased adiposity. Diet-induced obesity is frequently accompanied by insulin
resistance that disrupts glucose homeostasis (249). As seen from Figure 4-8 d, Inpp4b-/female mice had significantly increased fasting circulating glucose levels compared to WT
mice, especially when fed HFD. The non-fasting blood glucose was also elevated in HFD
Inpp4b-/- females (Figure 4-8 e). Consistently, the glucose tolerance test confirmed that
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Figure 4-6. INPP4B is required for mouse mammary gland side branching. (a-b) Mammary glands
were dissected from WT or Inpp4b-/- female mice at an age of 14 weeks. RNA was extracted,
reversed transcribed, and analyzed for Esr1 and Pgr expression by RT-qPCR using Krt18 as
control. (c) Whole mount of #4 mammary gland from WT and Inpp4b-/- female mice. (d) RNA from
(a-b) were analyzed for Agre expression by RT-qPCR using Krt18 as control.
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Figure 4-7. Loss of INPP4B activates AKT and PKC pathways. (a) MCF7 cells were transfected
with INPP4B siRNA, PTEN siRNA, and both INPP4B and PTEN siRNA. Proteins were isolated
and analyzed for INPP4B, PTEN, pPKCζ, pAKT, total AKT, and Tubulin by Western blotting. (bc) Quantification of pPKCζ (b) and pAKT (c) from (a). (d) Mammary glands were dissected from
WT and Inpp4b-/- female mice. Proteins were extracted and analyzed for pPKCζ and Tubulin by
Western blotting.

HFD Inpp4b-/- mice had significant increases in blood glucose levels and increased glucose
clearance times compared to controls, indicating that Inpp4b loss induces hyperglycemia
in obese female mice (Figure 4-8 f). Circulating insulin was determined within groups of 5
mice each. As seen in Figure 4-8 g, HFD Inpp4b-/- mice exhibited a trend toward higher
insulin levels compared to all other groups however it did not reach statistical significance
(p = 0.0805). Consistent with the role of INPP4B during insulin signaling seen in the mouse
model, gene expression analysis of the livers from nondiabetic (N=8) and Type 2 diabetic
(N=6) women (GSE15653) revealed that INPP4B expression was significantly decreased
in the livers of diabetic patients (Figure 4-8 h).
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4.2.7. Inpp4b loss leads to NAFLD in female mice fed HFD
The emergence of hyperglycemia is an indicator of liver dysfunction, a key organ that
regulates glycemic control. The liver weights of HFD Inpp4b-/- female mice were
significantly increased compared to the control mice (Figure 4-9 a). The histological
examination of H&E stained liver sections revealed that HFD Inpp4b-/- female mice
developed severe steatosis (Figure 4-9 b-c). The morphometric quantification of unstained
liver section areas, which identifies lipid droplets, indicated a significant increase of lipid
droplets in the livers of Inpp4b-/- female mice. Extensive macrovesicular steatosis was
observed in the hepatic lobes of HFD Inpp4b-/- female mice; microvesicular steatosis was
observed in knockout mice fed with LFD; and no steatosis was detected in WT females
(Figure 4-9 c). Consistently, Oil Red O staining confirmed the accumulation of fat within
the livers of HFD knockout mice compared to WT on the same diet (Figure 4-9 d). Sirius
red staining indicated an accumulation and expansion of collagen in the livers of HFD
Inpp4b-/- female mice, which is a defining characteristic of liver fibrosis (Figure 4-9 e).
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Figure 4-8. Loss of INPP4B caused weight gain and hyperglycemia in mice fed an HFD. (a)
Bodyweight of LFD WT (N=5), LFD Inpp4b-/- (N=7), HFD WT (N=16), and HFD Inpp4b-/(N=10) female mice were recorded every week till week 11. (b-c) Weights of visceral white adipose
tissue (WAT) and #4 mammary gland were compared in indicated groups at 16-17 weeks of age.
(d-e) Blood glucose level was measured after 6 hours fasting (d) or without fasting (e) in LFD WT,
LFD Inpp4b-/-, HFD WT, and HFD Inpp4b-/- female mice. At least 5 mice were included in each
group. (f) Oral glucose test of LFD WT (N=6), LFD Inpp4b-/- (N=6), HFD WT (N=11), and HFD
Inpp4b-/- (N=9) female mice. Mice were weighed and treated with 2 g/kg of glucose and blood
glucose was measured at different time points as indicated. (g) Blood insulin was measured using
a mouse insulin ELISA kit for the indicated groups (5 mice per group). (h) Comparison of INPP4B
expression in livers of subjects with or without type 2 diabetes. Data were exported from
GSE15653.
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4.2.8. Inpp4b loss caused hyperplasia in mammary gland and expansion in the
extracellular matrix (ECM)
Since INPP4B is a tumor suppressor in breast cancer, we examined whether Inpp4b
deficiency affects the mouse mammary gland morphology. H&E staining of the mammary
glands from WT and knockout females on HFD showed abnormal duct and alveolar
structures (Figure 4-10). We next used histological markers to distinguish the functional
layers of the mammary duct and examined the origin of the abnormal duct structures. The
luminal cells were identified by CK8 expression, myoepithelial cells were identified by
alpha smooth muscle actin (αSMA) expression, and the basal membrane was stained with
trichrome blue to visualize collagen fibers. As seen in Figure 8a, loss of INPP4B resulted
in end bud hyperplasia for mice fed either diet. In HFD groups, Inpp4b knockout females
had enlarged adipocytes compared to their WT. The myoepithelial layer remained similar
in all groups, however expansion of the epithelial layer occurred in the mammary glands
of Inpp4b-/- female mice fed either diet. Interestingly, Inpp4b loss resulted in the expansion
of the ECM surrounding both the end buds and ducts (Figure 4-11 a). Fibroblasts participate
in the formation of the ECM surrounding ducts by producing and secreting ECM molecules
including collagen (250). Using Trichrome staining, we showed that loss of INPP4B
promoted the accumulation of collagen surrounding the ducts in Inpp4b-/- females (Figure
4-11 b).
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Figure 4-9. Inpp4b depletion leads to NAFLD with fibrosis. (a) Liver weights of LFD WT (N=10),
LFD Inpp4b-/- (N=7), HFD WT (N=11), and HFD Inpp4b-/- (N=9) female mice. (b) Morphometric
quantification of the unstained area from H&E staining in LFD WT (N=9), LFD Inpp4b-/- (N=5),
HFD WT (N=11), and HFD Inpp4b-/- (N=6) female mice. (c) H&E staining of liver sections from
designated groups. (d) Oil Red O staining of frozen liver sections in HFD WT, and HFD Inpp4b-/female mice. (e) Sirius Red staining of liver sections from designated groups.
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Figure 4-10. INPP4B loss induced hyperplasia in end buds and duct of mouse mammary gland.
Representative image of H&E staining of mammary glands from HFD WT, and HFD Inpp4b-/males.

4.3.

Discussion

INPP4B has a well-documented tumor suppressor function in prostate and breast cancers
(29, 31, 46, 47). The downstream targets of INPP4B include the INSR/PI3K/Akt,
PLC/PKC, and steroid receptor pathways. Multiple groups, including our own, have shown
that INPP4B can suppress Akt signaling in malignant and nonmalignant epithelial cells and
mouse tissues. Additionally, we have shown that INPP4B also suppress PKC signaling in
multiple cell lines and mouse model (53, 54). Finally, our group has been the first to show
regulation of AR, ERα, and PR activity by INPP4B (54).
The early stages of breast cancer are ERα positive and estrogen dependent. We have
previously reported that INPP4B regulates AR activity in prostate cancer. Interestingly,
INPP4B is expressed in ERα+ breast cancers but was found histologically negative in triple-
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negative breast cancers, the most aggressive subtype (46, 99), which suggests a correlation
between INPP4B and ERα in breast cancer progression. Analysis of breast cancer
transcriptomes and proteomes showed that INPP4B positively correlates with ERα on both
the mRNA and protein levels in breast cancer patients (Figure 4-1) suggesting a functional
crosstalk exists between INPP4B and ERα signaling. In MCF7 cells, INPP4B knockdown
did not affect ERα expression, however it did regulate ERα transcriptional activity (Figure
4-2 a, c-d). INPP4B knockdown reduced the E2-mediated induction of SGK3, PGR,
UGT2B17, MSMB, and RAPGEFL1 (Figure 4-4 d-i). On the other hand, INPP4B reduced
the expression of EGR3 and CYP24A1, which are upregulated in rapidly proliferating cells
(Figure 4-4 c and h). A comparative gene hybridization analysis that measures copy
number in breast cancer identified CYP24A1 as a potential oncogene (251). We compared
the gene expression patterns after INPP4B and PTEN knockdown. A subset of genes was
altered with both INPP4B and PTEN knockdown. However, we demonstrated that a subset
of genes, including CYP24A1 and RAPGEFL1, were preferentially regulated by INPP4B
(Figure 4-2 f and Figure 4-4 h-i).
In this report, we show that loss of INPP4B leads to a reduction in PR RNA and protein
levels in both breast cancer cells and the normal mouse mammary gland (Figure 4-5 and
Figure 4-6). PR, a direct ERα target gene, is required for ductal branching and
alveologenesis in the mammary gland (228). PGR is expressed as two protein isoforms,
PRA and PRB (252). The PRA isoform predominately functions in uterine development
(253) and PRB functions in the mammary gland (254). PRB is sufficient to stimulate the
ductal branching (243, 254). In Figure 4-5, we showed that INPP4B was required for the
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Figure 4-11. Loss of INPP4B causes hyperplasia in the mammary gland and expansion of ECM.
(a) Mammary glands from 16 weeks old LFD WT, LFD Inpp4b-/-, HFD WT, and HFD Inpp4b-/female mice were sectioned, stained for CK8 or αSMA, and counterstained with hematoxylin.
Examples of TEB that stained positive for CK8 and αSMA were presented. (b) Trichrome staining
of mammary gland sections from LFD WT and LFD Inpp4b-/- mice.
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optimal expression of both PR isoforms in breast cancer cell lines, suggesting that Inpp4b
loss may affect mammary gland development similar to PR knockout models (243).
Indeed, loss of INPP4B led to a deficiency in the ductal side branching of healthy mouse
mammary glands (Figure 4-6). In the normal mammary gland, approximately 70% of
epithelial cells are ERα- and PR- and require stimulation from adjacent ERα+ and PR+ cells
to proliferate through paracrine signaling (255). ER- and PR- mediate the transcription and
secretion of amphiregulin, WNT4, and RANKL, which in turn, stimulate the proliferation
of ERα- and PR- mammary epithelial cells (255). Wnt4, RANKL, and the EGFR ligand
AREG, are PR target genes that have also been implicated in the regulation of ductal
branching (133, 256, 257). Amphiregulin is also an ERα target gene and its expression was
significantly reduced within the mouse mammary gland of Inpp4b knockout animals in
(Figure 4-6 d).
Multiple groups, including ours, have shown that INPP4B inhibits the AKT pathway.
PI3K/Akt signaling is activated in all advanced breast and prostate cancers concomitantly
with the loss of INPP4b and PTEN (29, 46, 132). We have shown INPP4B mediated
suppression of the PKC pathway in human prostate cancer cell lines and in the mouse
prostate (53, 54). However, nothing was previously known about the INPP4B regulation
of AKT and PKC signaling in physiologically normal organs.
The insulin receptor and fatty acid mediated signaling pathways lead to the
phosphorylation of AKT and PKC in the liver, muscle and adipose tissues, which affects
both glucose and lipid metabolism (258-260). The AKT and PKC pathways are associated
with metabolic disorders in obese or diabetic individuals. In this report, we show that AKT
and PKC pathways are activated by INPP4B knockdown in MCF7 cells, and in the
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mammary glands of Inpp4b-/- female mice. (Figure 4-7 a-d). Moreover, AKT and PKC
phosphorylation was increased in the livers of the Inpp4b-/- mice, suggesting a role for
INPP4B in the insulin response. To determine the role of INPP4B in metabolic health, we
designed 4 experimental groups: LFD WT, HFD WT, LFD Inpp4b-/-, and HFD Inpp4b-/females. The HFD, which contained 60% fat, did not increase the weight of the WT females
when compared to the LFD group. Remarkably, the Inpp4b-/- females were 50% heavier
compared to the HFD WT females. Correspondingly, the visceral fat weight in the
knockout group was increased on average by 400% compared to that of HFD WT females
(Figure 4-8 b-c). The increased visceral adiposity in humans frequently causes metabolic
dysfunction which is characterized by insulin resistance, dyslipidemia, and inflammation
(261). In our previous report, we showed that HFD Inpp4b-/- male mice developed type 2
diabetes. Despite extreme weight gains, HFD Inpp4b-/- female mice only developed
hyperglycemia. Estrogen signaling in females has been shown to protect against insulin
resistance and glucose intolerance in the HFD treated mice, which may contribute to the
gender differences within the metabolic phenotype of Inpp4b-/- mice (236). Approximately
70% of obese and 30% of lean individuals are metabolically unhealthy (175). Hepatic
accumulation of fat is the best marker of metabolic disease (184). The increased prevalence
of obesity and metabolic disorders in the US also increases the risk of developing NAFLD
(262). Indeed, HFD fed Inpp4b-/- females developed severe NAFLD and liver fibrosis
(Figure 4-9).
Diet-induced obesity increases the risk of developing breast cancer in premenopausal
women (263, 264). Here we showed that Inpp4b-/- female mice developed hyperplasia in
the end buds by 17 weeks old (Figure 4-10 and Figure 4-11). In addition, the deletion of

114

Inpp4b in female mice expanded the ECM of mammary tissue (Figure 4-11). The ECM is
composed of macromolecules including collagen, fibronectin and polysaccharides (265).
Using Trichome staining, we showed the accumulation of collagen surrounding the ducts
(Figure 4-11 b). Obesity increases differentiation of active fibroblasts leading to the ECM
remodeling which promotes breast cancer progression (266).
In this study, we systematically investigated the role of INPP4B in breast cancer models
and normal mouse physiology. In breast cancer cells, we showed INPP4B modulates ERα
transcriptional activity and stimulates PR expression. We show that while INPP4B and
PTEN have similar enzymatic activities, they are functionally distinct. In healthy mouse
mammary glands, INPP4B stimulates ductal side branching, due in part to its ability to
regulate ERα and PR activity, and it regulates the stromal sheath surrounding ducts and
alveoli. Adipose and hepatic INPP4B expression protected HFD-fed female mice from
developing hyperglycemia, NAFLD, and liver fibrosis.
4.4.

Materials and methods

Cell culture
The human breast adenocarcinoma cell line MCF7 and T47D were purchased from ATCC
(Manassas, VA). MCF7 cells were maintained in DMEM media (Thermo Fisher Scientific,
Waltham, MA) supplemented with 10% fetal bovine serum (FBS). T47D cells were
maintained in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA) supplemented with
10% FBS and 0.2 units/ml bovine insulin (Sigma, ST. Louis, MO). FBS and charcoal
stripped serum (CSS) were purchased from Sigma-Aldrich (St. Louis, MO). Estradiol (E2)
were purchased from Sigma.
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siRNA transfections
INPP4B and PTEN were knocked down by customer-designed INPP4B and PTEN siRNAs
(267) using non-coding siRNA as control (Thermo Fisher Scientific). Briefly, 20-40 nM
siRNAs were diluted in OPTI-MEM medium and transfected using Lipofectamine
RNAiMAX Reagent (Thermo Fisher Scientific) as recommended by the manufacturer.
Microarray and Gene Set Enrichment Analysis (GSEA)
MCF7 cells were transfected with 80 pmol control or INPP4B specific siRNAs as described
in the previous section. After transfection, cells were maintained in complete medium. At
the end of day 2, cells were treated with 100 nM of E2 for another 24 hours before harvest.
Total RNA was extracted, quantified, evaluated for quality, and analyzed using the
Illumina Human HT-12v4 expression Beadchip platform as described previously (268). To
investigate the correlation between INPP4B and ERα transcriptional activity, Gene Set
Enrichment Analysis was performed as previously described (267, 269). ERα signature
was generated from GSE8597 which includes 466 genes significantly changed (p<0.05)
after 24 hours of E2 treatment.
Gene expression analysis
RNA was prepared from breast cancer cells or mouse tissues using Tri Reagent (Molecular
Research Center, Cincinnati, OH). The RNA concentration was determined by NanoVue
Plus (GE Healthcare BioSciences, Piscataway, NJ). The real-time quantitative reverse
transcription (qRT-PCR) was performed using Verso cDNA synthesis Kit (Thermo Fisher
Scientific) and a Roche 480 LightCycler (Roche, Basel, Switzerland). The corresponding
primers and probes were designed from Universal Probe Library and were listed in Table
9.
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Table 9. Primers and corresponding probes used in CHAPTER 4.

Gene
ESR1
INPP4B
PTEN
PGR
PTPMT1
CHD5
HERC5
MT2A
MYOF
CALU
EGR3
SGK3
UGT2B17
MSMB
CYP24A1
RAPEGFL1

Human gene primers and corresponding probe sets
Forward primers
reverse primers
ttactgaccaacctggcaga
atcatggagggtcaaatcca
tgtctgatgctgacgctaaga
ccacaaaccaatccagcaa
ggggaagtaaggaccagagac
tccagatgattctttaacaggtagc
gggtgagactcttcatctatcca
tgcatctgttaccagccagt
cgaggttcctgtgcaactct
tgtggatgtatgaccggatct
ctccctaggcctgtttgtgt
agactcagaaacgccttcca
ggctctcacagtgccctact
atgaccaagttgcccatgtt
ctagccgcctcttcagctc
gcaggtgcaggagtcacc
tggtggggaagtggaagtaa
tcaggtaacaaggtccaaacg
gaggcccctccattactagc
tccctggatagaagagaattgg
cgcaagcgtgtgtgtttaag
ggggaagagtttggggtaaa
ctgactattctatagtgaatgccagtg
ggtgcataagagaaaccaacg
tgtcagaagaaagtgccaaca
gccatcaaatctccatagaacc
ggagtcctgcttatcacaatga
acgaaggtggcaaagatcac
tcatcatggccatcaaaaca
gcagctcgactggagtgac
ccctctgcaagcagaacc
gttgtccagccccatgac

probe
24
41
48
2
75
2
66
68
2
33
26
16
61
2
88
62

Gene
Esr1
Pgr
Agre

Mouse gene primers and corresponding probe sets
Forward primers
reverse primers
gctcctaacttgctcctggac
cagcaacatgtcaaagatctcc
tgcacctgatctaatcctaaatga
ggtaaggcacagcgagtagaa
aagaaaacgggactgtgcat
ggcttggcaatgattcaact

probe
97
72
73

Western blotting
The protein extraction from cultured cells (134) and mouse tissue (267) was previously
described. Cleared lysates were diluted to 4 µg/µl and 15-80 µg of protein was resolved on
a 7.5% - 12.5% SDS-PAGE. The protein was transferred using nitrocellulose or PVDF
membrane (0.2 μm) and the membrane was blocked using 5% BSA or non-fat milk. The
blot was incubated with primary antibodies against INPP4B, PTEN, PR, pAKT S473, total
AKT, pPKCζ T410, and β-tubulin. The sources and dilutions of antibodies are listed in
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Table 10. The signal was captured using a Gel Logic 2000 imaging system or ImageQuant
LAS 500 imager and analyzed by Carestream Molecular Imaging software (Carestream,
Rochester, NY) or ImageQuant TL software (GE Healthcare).
Table 10. Antibodies used in CHAPTER 4.
Antibody

cat #

concentration

RRID

phospho-Akt S473

Cell signaling #4051

1:1000

AB_331158

Total Akt

Cell signaling #4691

1:1000

phospho-PKCζ T410

Cell signaling #2060

1:1000

phospho-PKCβII S660

Cell signaling #9371

1:1000

INPP4B

Cell signaling #8450

1:1000

PTEN

Cell signaling #9188

1:1000

β-Tubulin

Millipore #05-661

1:5000

PR

Santa Cruz sc-810

1:600

AB_915783
AB_561487
AB_2168219
AB_10859372
AB_2253290
AB_309885
AB_628172

Animal studies
Inpp4b-/- mice and high-fat diet treated Inpp4b-/- mice were described previously and in
Chapter 2 (28, 54). WT and Inpp4b-/- females were fed with either LFD (LabDiet 5V75,
St. Louis, MO) or HFD (TestDiet 58R3, St. Louis, MO) for 12-13 weeks after wean. Mouse
body weights were recorded once a week. All LFD WT, LFD Inpp4b-/-, HFD WT, and
HFD Inpp4b-/- female mice were euthanized and dissected at 13 weeks, weighed and their
tissues were collected for gene expression, protein, and histological analysis. All protocols
were approved by the Florida International University Institutional Animal Care and Use
Committee.
Whole mount
Mouse #4 mammary gland fat pad were flattened onto a pre-cleaned glass slide and fixed
in ethanol/acetic acid (3:1) solution overnight at room temperature. Fixed tissues were
washed in 70% ethanol and distilled water. The staining solution was made by 0.2%
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Carmine red (Sigma) and 0.5% aluminum potassium sulfate (Fisher) in distilled water. The
slides were stained with Carmine Alum solution overnight, dehydrolyzed in graded
ethanol, cleared in xylene, and stored in toluene (Sigma).
Glucose tolerance test
The glucose tolerance test were performed on 14-week-old females as exact previously
described (54). Briefly, after overnight fasting, the mice were weight and gived 2 g/kg of
glucose by oral gavage. The blood glucose was tested at before administration, 30, 60, 90,
and 120 min after administration using glucose meter.
Histological analysis
The tissue sectioning, H&E staining, and immunoblotting were described previously (267).
Briefly, 4.5 µM sections were deparaffinized in xylene, hydrolyzed in gradient ethanol and
stained with hematoxylin and eosin. The level of hepatosteatosis was measured by counting
the surface of unstained areas per field in liver sections using ImageJ as described in
Chapter 2. For immunoblotting, the antigen was retrieved by heating in 10 mM sodium
citrate buffer. Sections were blocked then incubated with primary antibodies CK8
(#ab53280, Abcam, Cambridge, MA) and α-SMA (#ab5694) overnight at 4 °C. ABC kit
(Vector Laboratories, Burlingame, CA) and Peroxidase substrate kit (Vector Laboratories)
were used to visualize the staining as suggested by instruction.
Sirius Red Staining
Sections were processed in xylene and gradient ethanol. Slides were stained in 0.4% Sirius
Red staining reagent (Lucerna-Chem, Switzerland), soak in 0.5% acidic acid, and
processed in distilled water, ethanol and xylenes before mounting.
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Oil Red O staining
Fresh liver tissue was placed in OCT medium and snapped frozen in liquid nitrogen. Liver
samples were cut at 12 μm sections and attached to glass slides. Oil red O was dissolved
in hot propylene glycol and filtered through Whatman #2 filter paper. Slides were fixed in
4% PFA, rinsed in distilled water and in propylene glycol, stained in oil red O, and
counterstained with hematoxylin. All images were acquired using an AxioCam MRc5
camera (Zeiss, Thornwood, NY).
Trichrome Staining
After deparaffinization and hydration, slides were fixed in Bouin’s solution (Sigma,
#HY10-1) at 56 °C for 20min. Slides were stained in sequence of Weigert’s Iron
Hematoxylin (Sigma, #HT1079), Biebrich Scarlet-Acid Fucshin (Sigma, #HT15-1),
Phosphotungstic/Phosphomolybdic acid solution, Aniline Blue solution (Sigma, #15-4),
1% acetic acid. After washing, the slides were dehydrated and cleared in xylenes before
mounting.
Statistics
Student t-tests were used to test for inequality of means from two independent samples.
Two-way ANOVA was performed for experiments related to the HFD-treated experiment
by Prism 7.0. P-values less than 0.05 were considered statistically significant. Values are
present as mean ± SEM. All cell culture-based experiments were repeated at least three
times and biological triplicated were used for each point. In the mouse-based analysis,
samples from at least 8 mice were used unless stated otherwise.
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS
INPP4B is a tumor suppressor in breast, prostate, and other cancers (29, 31, 46, 155), which
acts as a dual-specificity phosphatase similar to another tumor suppressor PTEN. While
INPP4B is highly expressed in various tissues in both human and mouse ice and humans
(Figure 1-5), very little is known about its physiological function. In my dissertation
research, I investigated the function of INPP4B in modulation of tumor-promoting
androgen and estrogen signaling, as well as in metabolic health.
In the first experimental part of the dissertation (Chapter Two), I demonstrated that
INPP4B regulates AR transcriptional activity in part through AKT and PKC pathways.
INPP4B-dependent regulation of the proteome in androgen-dependent prostate cancer cell
line LNCaP was investigated using reverse phase protein arrays (RPPA). INPP4B
knockdown significantly elevated the phosphorylation levels of oncogenic kinases
including SRC, MAPK, and AKT, while the protein level of tumor suppressor RB1 was
significantly reduced. Both overexpression and downregulation of the epigenetic regulator
Enhancer of zeste homologue 2 (EZH2) have been described in aggressive cancer (270273). In LNCaP cells, EZH2 levels significantly decreased following INPP4B knockdown.
INPP4B was also required for the optimal expression of EZH2 in androgen independently
derived prostate cancer cell line, VCaP, as well as in mouse ventral prostate. In our previous
study, we showed that one-year-old mice develop hyperplasia without the observation of
neoplastic transformation (267) suggesting the downregulation of EZH2 might play a
compensatory role in mouse prostate of Inpp4b-/- males in preventing the development of
the prostate cancer. Currently, specific EZH2 inhibitors like GSK126 have been used in
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clinical trials for CRPC patients (274, 275). In future studies, we will investigate whether
EZH2 reciprocally regulates INPP4B signaling.
In Chapter 3, I showed loss of INPP4B induced high levels of inflammatory cytokines (Il6,
Tnf, and Il1b) and adipokines (Leptin/Adiponectin), which are risk factors for prostate
cancer (213). Levels of these cytokines are further elevated by diet-induced obesity in
Inpp4b-/- male mice leading to the development of high grade prostatic intraepithelial
neoplasia. In addition to systemic and local inflammation in knockout males, I found that
INPP4B is a major regulator of metabolic health in both lean and obese mouse model.
Specifically, I showed that INPP4B protects against liver steatosis. Using RNA-sequencing
and pathway analysis, I demonstrated that Inpp4b knockout activates lipid transfer,
synthesis, and storage pathways leading to the accumulation of lipids in mouse livers,
insulin resistance, and ultimately to the development of type 2 diabetes (T2D). Under the
diabetic condition, the insulin signaling activates AKT pathways which promotes the
proteolysis of SREBP1. SREBP1 further activates PPARγ expression, and together these
transcription factors stimulate expression of a subset of genes that are involved in lipid
uptake and synthesis. This process eventually leads to hepatic lipid accumulation.
Interestingly, the pathway analysis also showed that Inpp4b knockout regulates the
metabolism of histidine, arginine, and proline. Histidine metabolism was recently found to
increase the tumor cell resistance to a chemotherapeutic drug, methotrexate (276). Arginine
and proline metabolisms are tightly associated with neurodegenerative diseases such as
Parkinson’s disease (277).
In Chapter 4, I demonstrated that INPP4B regulates ERα transcriptome. INPP4B
knockdown reduces the level of a subset of ERα direct target genes, including PR, and
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inhibits mammary gland side branching. Previous studies have shown INPP4B is lost in
most of the triple-negative breast cancers (TNBC) and might be the best prognostic marker
for TNBC with the odds ratio of 108 (46, 99). However, the role of INPP4B in HER2
positive breast cancers is unknown. HER2 is a human homolog of the murine ERBB2,
whose overexpression in mouse induces mammary gland tumors similar to human HER2
positive tumors. Using MMTV-Erbb2 overexpressing mice, I tested whether the loss of
INPP4B accelerates cancer progression. I mated the Inpp4b-/- mice with MMTV-Erbb2
transgenic mice to generate the MMTV-Erbb2;Inpp4b-/- female mice. Both MMTV-Erbb2
and MMTV-Erbb2;Inpp4b-/- female mice were subjected to either a low-fat diet or a highfat diet (HFD). We noticed that the loss of INPP4B increased tumor incidence and
worsened the survival of mice regardless of the diets. Remarkably, the diet was irrelevant
to control females. Only in MMTV-Erbb2;Inpp4b-/- female mice, HFD accelerated tumor
progression. In future studies, we will continue to investigate the molecular mechanism
behind this phenomenon.
We are the first to investigate the INPP4B role in metabolism. We discovered that
metabolic regulation by INPP4B is sexually dimorphic. In obese males, Inpp4b-/- mice
have significantly elevated blood glucose, insulin resistance, and gluconeogenesis, which
is consistent with T2D. In females, a combination of Inpp4b knockout and HFD cause
hyperglycemia but do not impair insulin sensitivity. HFD Inpp4b-/- female mice develop
a more severe nonalcoholic fatty liver disease (NAFLD) with liver fibrosis compared to
obese male mice. In future studies, we will perform RNA sequencing to explore gender
differences in metabolic health between male and female Inpp4b-/- mice.
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The liver is not only crucial for glucose homeostasis and lipid metabolism, it also plays an
essential role in drug detoxification. This liver function is also sexually dimorphic. Female
and male individuals have a different expression pattern of cytochrome p450s (CYPs), key
enzymes that are involved in drug and xenobiotic metabolism. Interestingly, analysis of the
RNA sequencing results from livers of WT and Inpp4b-/- male mice indicated that the
genes upregulated in liver of Inpp4b-/- males, such as Cyp2b9 and Cyp2b13, are originally
highly expressed in WT females (207). The loss of INPP4B causes a female-like expression
pattern of CYPs in the male liver, suggesting that INPP4B might be a key regulator of
sexual dimorphism of drug metabolism. In the follow-up studies, we will explore
physiological consequences of the feminization of the Inpp4b-/- male livers. We will
compare the RNA sequencing data and xenobiotic metabolism between male and female
livers of WT and Inpp4b-/- mice. This will provide more evidence to evaluate whether
Inpp4b regulates sexual dimorphism in the liver.
In summary, my dissertation research has demonstrated that INPP4B is a tumor suppressor
that regulates steroid hormone signaling in prostate and breast cancer cells. Importantly for
normal physiology, INPP4B protects against metabolic disorders and obesity.
I experimentally demonstrated that INPP4B regulates steroid receptor transcriptional
activity in prostate and breast cancers. I revealed that INPP4B might be a regulator of lipid
storage and gender-specific xenobiotic metabolism in obese mice. When feed with HFD,
both Inpp4b-/- male and female mice developed hyperglycemia but only male have insulin
resistance and progressed to T2D. In obese models, loss of INPP4B caused metabolic
changes eventually lead to development of fatty liver disease which progresses to liver
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fibrosis. Thus, I elucidated tumor-suppressive actions of INPP4B and determined that
INPP4B is a major determinant of metabolic health.
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APPENDIX
Buffers used in ChIP assay
SDS Lysis Buffer (100 ml)
10 ml 10% SDS
2 ml 0.5 M EDTA pH 8.1
5 ml 1 M Tris-HCl pH 8.1
Bring to 100 ml with water
ChIP Dilution Buffer (500 ml)
27.5 ml 10% Triton X-100
1.2 ml 0.5 M EDTA pH 8.1
8.4 ml 1 M Tris-HCl pH 8.1
16.7 ml 5 M NaCl
Bring to 500 ml with water
Low Salt Immune Complex Wash Buffer (500 ml)
5 ml 10% SDS
50 ml 10% Triton X-100
2 ml 0.5 M EDTA pH 8.1
10 ml 1 M Tris-HCl pH 8.1
15 ml 5 M NaCl
Bring to 500 ml with water
Elution Buffer (10 ml) is made fresh the day of use.
1 ml 10% SDS
1 ml 1 M NaHCO3
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8 ml water
TE Buffer (500 ml)
5 ml 1 M Tris pH 8.1
1 ml 0.5 M EDTA pH 8.1
Bring to 500 ml with water
High Salt Immune Complex Wash Buffer
Add 1.02 g NaCl to 50 ml of Low Salt Immune Complex Wash Buffer
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KEGG pathways significantly affect by Inpp4b knockout
KEGG pathway analysis
INPP4B KNOCKOUT compared to WT
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KEGG_TRYPTOPHAN_METABOLISM
KEGG_PROPANOATE_METABOLISM
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRA
DATION
KEGG_PEROXISOME
KEGG_GALACTOSE_METABOLISM
KEGG_BUTANOATE_METABOLISM
KEGG_PYRUVATE_METABOLISM
KEGG_BETA_ALANINE_METABOLISM
KEGG_HUNTINGTONS_DISEASE
KEGG_RETINOL_METABOLISM
KEGG_ETHER_LIPID_METABOLISM
KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_A
CIDS
KEGG_ARGININE_AND_PROLINE_METABOLISM
KEGG_PENTOSE_PHOSPHATE_PATHWAY
KEGG_NITROGEN_METABOLISM
KEGG_LYSINE_DEGRADATION
KEGG_GLYCOLYSIS_GLUCONEOGENESIS
KEGG_CARDIAC_MUSCLE_CONTRACTION
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GO biological functions significantly affected by Inpp4b knockdown
GO enrichment analysis
INPP4B KNOCKOUT compared to WT
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